Board of Overseers

Chairperson
Dr. Ruth L. Gottesman*

Chairpersons emeriti
Burton P. Resnick* Robert A. Belfer* Ira M. Millstein*

Executive Committee
Michael F. Price*

Vice Chairpersons
Zygmunt Wilf*
Elliot K. Wolk*

Treasurer
Roger W. Einiger*

Philip Altherr*
Linda Altman*
Irving F. Baumrind
Diane Belfer
Renee E. Belfer
Robert A. Bernhard
Roger Blumenkrantz
John D. Cohen
Kevin Davis
Dr. Gerald Domanski, ’68
Joan K. Eigen
Betty Feinberg
Bambo Felberbaum
Peter Gatoft
Jay N. Goldberg
Rosalyn Goldblatt
Arthur Hershaft
Morton P. Hyman
Michael Josselson
Richard M. Joel
Nathan Kahn*
Ernest Kalman
Marilyn Katz
Stanley M. Katz*
Paul J. Kossenberg*
Charles A. Krauss
Dr. Ira Kukin
Emily Fisher Landau
Hirschell E. Levine
Dr. Evelyn Lipper, ’71

Ronald J. Lasak*
Sylva Olneck
Arnold S. Pines
Joel I. Picket
Toby G. Ritter
Rita Rosen
Howard J. Rubenstein
Larry B. Scheinfeld
Dr. Lawrence Scherr
Harvey Schulweis
David A. Tanner
Daniel R. Tishman*
Louis R. Tomson
Samuel G. Weinberg*
Mony J. Weiss
Dr. David Wisotsky, ’74

Life Overseers
Philip Rosen

Honorary Overseers
Paul R. Chanin
Jerry S. Handler
John J. Pomerantz

*Executive Committee
Einstein Today

Welcome to the first annual report from the Albert Einstein College of Medicine. The pages that follow will acquaint you with the many new and exciting things that are happening on campus.

Einstein is the College of Medicine of Yeshiva University, whose slogan, “Bring wisdom to life,” is embraced by all of us in the Yeshiva community. In that same spirit of service to humanity, the new Einstein motto — “Science at the heart of medicine” — proudly proclaims the core values of our institution. Our new logo (see cover) stresses our new identity — simply “Einstein.” It also contains a modern image that perfectly links the worlds of science and medicine: the winding staircase from our recently opened Price Center/Block Research Pavilion, which represents the DNA double helix.

“Science at the heart of medicine” reflects everything that we do at Einstein. It represents the exceptional science that we pursue, which profoundly affects the education that our students receive and the medical care we practice, both locally and around the world. The phrase also captures the “humanism” that is the driving force behind Einstein’s unique culture. This quality is reflected in the intense level of collaboration among our scientists, as well as in the caring and compassionate approach taken by our faculty and students.

Perhaps most important, the College of Medicine is dedicated to carrying on the legacy of our namesake, Albert Einstein. The words and deeds of this brilliant scientist and humanist — known affectionately as “Uncle Albert” on campus — continue to guide the College of Medicine today, more than 50 years after his death. His philosophy and passion inspire and motivate Einstein’s diverse faculty, students, and alumni, who work daily to bring about a better future for people everywhere.

“As America’s oldest and largest Jewish university, Yeshiva is a citadel of Jewish learning and an academy that spreads wisdom through its renowned graduate schools of medicine, law, psychology, and social work. Einstein’s unique educational approach to training compassionate physicians fully personifies Yeshiva’s traditions and goals.”

RICHARD M. JOEL, President, Yeshiva University
“In the years ahead, I know that our talented investigators and well-trained graduates will be guided by ‘concern for man and his fate’ in whatever they do.”

**ALLEN M. SPIEGEL, M.D.**
The Marilyn and Stanley M. Katz Dean

---

**Einstein is getting even better.** That’s the inescapable message of this annual report. The newly recruited faculty, new programs, and new facilities described in these pages show that we’re building on Einstein’s traditional strengths: outstanding productivity and innovation; superb researchers working collegially; committed and caring students; and dedicated faculty.

As we make this great medical school even greater, we are following our recently developed strategic research plan. It emphasizes building bridges between basic and clinical investigators, with the goal of improving human health. That plan has guided our successful recruitment of new investigators whose work complements and amplifies our ongoing research at Einstein.

Since becoming Einstein’s dean in 2006, I’ve stressed the need for translational research — the rapid transfer of knowledge from the laboratory to the clinic for the benefit of patients. The new programs described in this report — in epigenomics, stem-cell research, and community-based cancer prevention and control — have significantly strengthened that research focus.

Thanks to our recent expansion across Morris Park Avenue, we’ve developed a true campus, unique among medical schools in New York City. The jewel of our campus is the award-winning Michael F. Price Center for Genetic and Translational Medicine/Harold and Muriel Block Research Pavilion, which was dedicated last June.

All this is made possible by the generosity of more than 5,000 dedicated supporters each year. Our fiscal year 2008, concluded on June 30, was special indeed: a year in which philanthropy generated more than $62 million in new gifts and pledges.

We have been extremely fortunate to benefit from leading investments by members of Einstein’s Board of Overseers — exemplified by major gifts from the Gottesmans and Katzes — as well as the support of alumni, foundations, corporations, the dedicated members of our Women’s and Men’s Divisions, and many other Einstein donors.

Yet as I write this, the health of the planet and its people is jeopardized by wars, climate change, and a severe financial crisis. Worldwide plagues such as AIDS, tuberculosis, and malaria stubbornly resist eradication efforts. And here in the U.S., our healthcare crisis grows ever more severe as patients’ access to care worsens and health costs escalate unsustainably.

“Concern for man and his fate must always form the chief interest of all technical endeavors…Never forget this in the midst of your diagrams and equations,” our namesake, Albert Einstein, advised. In the years ahead, I know that our talented investigators and well-trained graduates will be guided by “concern for man and his fate” in whatever they do.

As Einstein confronts the challenges that face us globally and at home, it is reassuring to know that we will move forward with your full support. I am sincerely grateful for all you have done for us and for what you continue to make possible.

**Allen M. Spiegel, M.D.**
The Marilyn and Stanley M. Katz Dean
I have been a part of Einstein for the past 40 years. For the first 33 of them I was a faculty member in the department of pediatrics and worked at the Children’s Evaluation and Rehabilitation Center. When I retired, I joined Einstein’s Board of Overseers, and one year ago became its chair. As I tell friends and colleagues, Einstein gets in your blood!

I have a deep love for this remarkable institution; for the splendid education it provides its medical and other graduate students, as well as for its services to children and adults with a wide range of developmental disabilities. Our medical students are an unusual group — so caring and passionate about the communities they are being trained to serve, both in the U.S. and in developing countries. Throughout my association with Einstein, it has been inspiring to watch our students mature and grow, and to see them go out into the world as compassionate physicians.

Of course, I also have enormous respect for the brilliant physician-scientists at Einstein who are dedicated to improving the human condition. One of the major strengths of Einstein is research, which fills almost all the buildings on our campus. We are very excited about our new Price Center/Block Research Pavilion. This state-of-the-art building is populated by some of the brightest minds any institution could claim. At this time in its history, Einstein sits squarely at the forefront of the new frontier of medicine.

It’s a special honor to be the first faculty member as well as the first woman to serve as chair of the Board during this crucial phase of Einstein’s existence. I am grateful that this phase of my life allows me to devote a good deal of time and energy to Einstein, and I try to inspire others to come to know Einstein in the ways that I know it.

I am also very fortunate to be able to invest financially in the institution I care so much about. My husband and I have been supporters for many years, and we were pleased to make a significant commitment this past year to advance both sides of Einstein’s mission: innovative medical education, and cutting-edge biomedical research.

We’re trying to do our part to ensure that Einstein will maintain the standard of excellence for which it will be renowned for generations to come — but we are far from alone, as you can see from the publication you now hold in your hands.

This annual report is a celebration of the work made possible by thousands of supporters — past, present, and future — who join together each year to invest in this special college of medicine. We are very grateful for your continued and thoughtful generosity.

Ruth L. Gottesman, Ed.D.
Chair, Einstein Board of Overseers
Vitamin D and Mortality Risk
The next time you have a routine blood test, ask to have your vitamin D level checked. In a large-scale study, Einstein scientists found that people with low levels of vitamin D in their blood face an increased risk of death from all causes compared with people who have higher levels.

Progress Against Aging
Maintaining organs’ efficiency in getting rid of damaged proteins may be a key to longevity, Einstein scientists have shown. By splicing a gene into mice, the researchers for the first time prevented the age-related decline of an entire organ — the liver. The findings suggest that drugs exerting a similar effect might allow people to live healthier lives well into old age.

Strokes Traced to Too Much Sleep
Oversleeping could be a risky habit. Einstein scientists found that postmenopausal women who regularly sleep more than nine hours a night may increase their risk of strokes caused by blood clots. Their stroke risk was 60 to 70 percent higher than for women who sleep for seven hours.

Heart Disease and Weight
Being obese is not always a prelude to heart disease. After studying a nationally representative sample of Americans, Einstein scientists found that a considerable proportion of overweight people are healthy, while quite a few normal-weight Americans have cardiovascular problems.

Short-Circuiting Migraines
Migraine sufferers may soon have a drug-free treatment option. In a study led by Einstein researchers, a hand-held magnetic stimulation device helped patients who used it at the first sign of a migraine. Thirty-nine percent of patients were pain-free two hours after treatment, compared with only 22 percent in a control group using a sham device.
Optimizing Cancer Therapy
By measuring the activity of four genes in cancer cells, Einstein researchers correctly predicted whether patients’ colorectal tumors were sensitive or not to a major chemotherapy drug. The advance could help doctors choose the most effective drugs for cancer patients.

New Longevity Genes
In the latest results from their search for anti-aging genes, Einstein scientists found that mutations in genes governing an important cell-signaling pathway help people live longer. A drug that does the same thing is now being tested as a cancer treatment and could prove helpful in delaying aging.

Re-engineered Immune Cells Show Promise Against AIDS
By outfitting immune-system killer cells with a new pair of genes, Einstein researchers transformed them into potent weapons that destroy cells infected with HIV. The finding could lead to an entirely new approach for combating AIDS and other viral diseases.

Zapping Viral Cancers
An experimental therapy shows promise against the many types of cancer caused by viruses. By attaching radioactive isotopes to antibodies, Einstein researchers have created a novel weapon with potential for treating cervical cancer, liver cancer, and other virus-induced cancers.

Help Against Hemophilia
Einstein scientists showed for the first time that transplanted liver cells can cure hemophilia A (the most common form of the disease) in an animal model. The principle established by this study might also help in treating hemophilia B.

“Fat” Genes Uncovered
By discovering the genes responsible for storing fat in cells, Einstein researchers have solved one of biology’s fundamental questions. The breakthrough could lead to new strategies for treating obesity and the diseases associated with it.

Eat Your Greens, Protect Your Heart
A diet rich in leafy vegetables may minimize the tissue damage caused by heart attacks. The finding by Einstein scientists suggests that the chemical nitrite, found in many vegetables, could be the secret ingredient in the heart-healthy Mediterranean diet.

“During 2008, the Einstein faculty published some 800 articles in peer-reviewed scientific journals. But even more important than our impressive productivity, our discoveries are having a real impact. They are improving people’s health in many different ways.”

Harry Shamoon, M.D., Professor of Medicine and Associate Dean for Clinical & Translational Research
At Einstein, the generosity of our donors is responsible for transforming our dreams of scientific progress into reality. The Gottesmans’ $25 million gift has created two new research centers — in Stem Cell and Regenerative Medicine and in Epigenomics — and a Clinical Skills Training Center to better educate the physicians of tomorrow.

DR. RUTH L. GOTTESMAN

Prior to joining the Einstein Board of Overseers in 2002, Dr. Ruth Gottesman, a specialist in the diagnosis and treatment of learning disabilities, enjoyed an academic career at Einstein that spanned more than three decades. In 1968, she joined Einstein’s Children’s Evaluation and Rehabilitation Center (CERC) to develop a program for children with dyslexia and other learning disabilities. She went on to serve as CERC’s director of psychoeducational services and, later, as director of the Adult Literacy Program. In 1999, she became founding director of the Fisher Landau Center for the Treatment of Learning Disabilities, a division of CERC that provides interdisciplinary services to individuals of all ages with learning disabilities.

What motivated the Gottesmans to make a gift of this magnitude? “Investing in Einstein is the best way we know to help ensure that the world we leave to future generations will be a healthier one,” says Ruth Gottesman.
Gottesmans’ gift puts Einstein at forefront of biomedical research

In early 2008, Einstein received a major gift of $25 million — one of the largest in our 53-year history — from Ruth L. and David S. Gottesman.

Focusing on three areas of vital importance to the mission of the medical school, the funds from the Gottesmans’ gift will be allocated as follows: $15 million will establish the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research; $7 million will support the Center for Epigenomics; and $3 million will be used to create the Ruth L. Gottesman Clinical Skills Facility. The two research programs will be based primarily at the Price Center/Block Research Pavilion; the training center will be housed in the soon-to-be-renovated Van Etten building. In addition, the gift will support an endowed chair at the Gottesman stem-cell institute and a faculty scholar in epigenomics, as well as the recruitment of top-flight faculty, solidifying Einstein’s leadership in these important fields.

“In discussions with the College of Medicine, we determined that stem cells, epigenomics, and clinical training were areas where we could help make an important contribution, both to Einstein and to the future of biomedical research,” explains Dr. Gottesman. “We want our gift to support endeavors that will position Einstein to excel in research and medical education, while also attracting the best and brightest to our laboratories and to our classrooms.”

“For more than three decades, Ruth Gottesman served Einstein with distinction as a talented and caring therapist, educator, and administrator. With this most generous gift from Ruth and her husband, David, the Gottesmans will continue to guide this institution and enhance our ability to improve the nation’s health.”

EDWARD R. BURNS, M.D., Executive Dean and Professor, Departments of Medicine and Pathology
“Einstein’s new institute will need enough investigators for engaging in the basic science of stem cells and regenerative medicine and for carrying out the translational research that brings our findings into the clinic.”

ERIC E. BOUHASSIRA, PH.D.

STEM-CELL RESEARCH GETS ITS OWN INSTITUTE

Eric E. Bouhassira, Ph.D., the Ingeborg and Ira Leon Rennert Professor of Stem Cell Biology and Regenerative Medicine at Einstein, points to the shortage of U.S. researchers who can apply stem-cell science to the treatment of human diseases.

Einstein’s new Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research “will need enough investigators for engaging in the basic science of stem cells and regenerative medicine and for carrying out the translational research that brings our findings into the clinic,” says Dr. Bouhassira.

The institute’s stem-cell work focuses on human embryonic stem cells. Since these cells can develop into virtually any type of cell in the body, they offer tremendous potential for improving human health. Dr. Bouhassira is well on the way to directing human embryonic stem cells to develop into adult red cells that could save the lives of people needing blood transfusions.

“Regenerative medicine” involves transplanting stem cells or other cells that multiply and restore lost or diseased tissue. Recently, Einstein’s Sanjeev Gupta, M.D., cured hemophilia in mice by transplanting healthy liver cells into the animals — a major advance against this most common form of the disease.
A New Nexus for Liver Transplants and Cell-Therapy Research

The Liver Transplant Program at Montefiore Medical Center, the University hospital for Einstein, is the first of its kind in the Bronx — a region with one of the highest rates of liver disease in the country.

“This newly established program fills a significant, unmet medical need for people who live in the Bronx and suffer from end-stage liver disease,” says Steven M. Safyer, M.D., president and CEO of Montefiore and an Einstein alumnus (’82).

Significantly, the transplant program is part of a collaboration between the Einstein Liver Center and Montefiore Medical Center — a nexus for basic and translational research on liver disease being carried out by scientists at the two institutions.

One of those scientists is Sanjeev Gupta, M.D., professor of medicine and of pathology at Einstein and a longtime member of the liver center. He is working on strategies for turning human embryonic stem cells into fully functional liver cells that could be transplanted into the body.

In time, this cell-therapy research could result in new treatment approaches for liver failure, hepatitis, and other liver disorders and might eliminate the need to replace the entire organ.

“The liver transplant program is welcome news for patients and those of us who are involved in liver research,” says Dr. Gupta. “The program’s clinical resources will help us develop suitable protocols to launch early cell-therapy studies in liver patients.”

ALPERN FAMILY FOUNDATION

The Alpern Family Foundation has given $1.5 million in support of a Core Facility for Stem Cell Research and Regenerative Medicine at the Price Center/Block Research Pavilion. The Alpern family and the foundation have been outstanding partners with Einstein for many years.

“Stem-cell research holds the key to many illnesses that cause untold human suffering. We are delighted to support Einstein investigators in their determined efforts to rid the world of cancer, cerebral palsy, and other debilitating diseases,” says Martin H. Schneider, Esq., president, Alpern Family Foundation.

MARIE MARKUS ESTATE

The estate of Marie Markus has made a gift of $1 million in support of stem-cell research.

ROSSYN GOLDSchein

Einstein Overseer

ROSSYN AND LESLIE GOLDSchein

Roslyn and Leslie Goldstein, leading supporters of stem-cell research at Einstein, made a gift this year of $500,000 to support the work of Mark Mehler, M.D., bringing their total commitment to $2 million.

“Several years ago, my husband Les and I were listening to the President when he announced that the federal government would not support stem-cell research. And I said, ‘Maybe they’re not, but we are!’” recalls Mrs. Goldstein.

“Cures have not yet been found for so many diseases, and we feel that stem-cell research is integral to those cures. We’re proud of Einstein’s position at the leading edge of this exciting new research arena.”
Gottesmans’ Gift

Epigenetic Modifications Fuel Many Types of Cancer

The genes in our cells are controlled by chemical “marks” that attach to DNA and turn genes on or off. Such so-called epigenetic control orchestrates normal development — making liver cells divide into other liver cells, for example. But aberrant epigenetic control can lead to cancer, and researchers have found abnormal epigenetic changes in every type of cancer they’ve studied.

The main epigenetic modification — in normal development and in cancer — involves adding methyl (CH₃) groups that act like switches to turn genes off.

The photomicrograph at upper left, from Dr. John Greally’s laboratory, shows varying degrees of epigenetic control within the nucleus of a normal, sperm-producing mouse cell. The red areas contain relatively few methylated (silenced) genes; areas stained green are highly methylated (i.e., many silenced genes are present); and other areas of nuclear DNA are stained blue.

Scientists have identified some 70 genes epigenetically silenced in cancer — mostly tumor-suppressor genes needed to keep cancerous changes at bay. Fortunately, epigenetic changes are reversible. By identifying abnormal alterations associated with cancer, Dr. Greally’s research may lead to drugs that remove these marks and thereby treat or even prevent cancer.

“Epigenomics is an exciting new field, and I’m hopeful that my research here at Einstein could lead to treatments or even cures for diabetes and other complex diseases.”

Reid Thompson, M.D./Ph.D. Student
**DELVING INTO EPIGENOMICS**

It’s well known that mutations to DNA can cause disease by impairing important genes. But diseases can also result from changes in gene activity that don’t occur through mutations but instead result from chemical alterations of genes.

These “non-DNA” influences are known as epigenetic changes — and they’re essential to life. For example, epigenetic modifications that silence some genes and turn others on dictate whether a stem cell becomes a kidney cell, a muscle cell, or some other cell type in the body.

Problems occur when epigenetic control goes awry, and genes get turned on or off when they shouldn’t. Studies show that errors in epigenetic signaling contribute to aging and numerous diseases, including diabetes, congenital disorders, and many types of cancer. Interestingly, in contrast to DNA mutations, epigenetic changes are reversible — raising the real possibility of correcting epigenetic glitches using drugs or other therapies to improve the health of people of all ages.

Our total repertoire of epigenetic mechanisms is referred to as our epigenome, which is now under intense study at Einstein. The College of Medicine’s new Center for Epigenomics — one of only a few in the U.S. — gives Einstein scientists access to the newest technologies for uncovering the epigenetic control mechanisms that so greatly influence human health.

“Our goal over the next five years is to make Einstein a world leader in studying the epigenomic dysregulation that occurs in human disease,” says John Greally, M.B., B.CH., Ph.D., who directs Einstein’s epigenomics center. “When scientists ask, ‘Who are the experts on the epigenetics of kidney disease or cardiovascular disease?’ for example, the next thing they’ll think is, ‘Someone at Einstein has got to be working on that.’”

The field of epigenomics is already aiding in cancer diagnostics. Using epigenomic profiles of leukemia patients’ cancer cells, scientists can determine which patients are likely to benefit from chemotherapy. And manipulating the epigenome for therapeutic purposes is now within reach.

“Since epigenomic regulation is inherently reversible, we have great hopes that if an epigenetic pattern has gone wrong, then we should be able to correct it with very specific therapies,” says Dr. Greally. He notes that Einstein researchers are now testing drugs that show promise in correcting the epigenetic regulation of breast cancer tumors.

---

**HIGH Q FOUNDATION**

The High Q Foundation has given $367,652 to support epigenomics research at Einstein. The foundation supports research that focuses on the discovery of treatments for Huntington’s disease.
A FACILITY FOR LEARNING ESSENTIAL SKILLS

Einstein has long emphasized the importance of equipping students with the skills essential for becoming well-rounded physicians — skills ranging from carrying out physical exams to communicating with patients. But the College of Medicine has lacked a facility dedicated to teaching those skills.

That will change in 2009, when Einstein opens its new Ruth L. Gottesman Clinical Skills Facility in renovated space in the Van Etten building. Plans call for 22 fully equipped examination rooms where students will be tested on physical diagnosis, examination techniques, patient-interviewing skills, and procedural skills such as venipuncture. Each room will have a computer-linked videocam system and one-way mirrors to facilitate observation and feedback.

Felise Beth Milan, M.D., a 1988 Einstein alumna, directs the Clinical Skills Assessment Program as well as the Introduction to Clinical Medicine course. She hopes that the new facility will set the stage for acquiring exciting new teaching technologies such as patient simulators. These surprisingly realistic mannequins can be used to teach and test many essential skills, including intubation, resuscitation, and pelvic exams. “By practicing on these mannequins, students will achieve a much greater skill level before they are actually dealing with live patients,” says Dr. Milan.

ROBERT M. BEREN AND FAMILY

The Robert M. Beren Foundation, together with the foundations of Mr. Beren’s children, made a gift of $360,000 in honor of Dr. Ruth L. Gottesman, a longtime friend of Mr. Beren. This gift will name a component of the Ruth L. Gottesman Clinical Skills Facility in memory of Mr. Beren’s uncle, Harry H. Beren, who was a Benefactor of the College of Medicine during his lifetime.

“All of our family has admired Ruth’s skills and her devotion to Einstein during her many years as a professor,” says Mr. Beren. “Now, as chair of the Board of Overseers, she further adds her special passion to take the College of Medicine to a new level of achievement.”

Robert M. Beren is president of the Robert M. Beren Foundation, Inc. and chairman emeritus of the Board of Trustees, Yeshiva University.
“Preparing students to deliver care that is both highly competent and highly compassionate is the guiding philosophy of medical education at Einstein.”

FELISE BETH MILAN, M.D. ’88
Director of Einstein’s Clinical Skills Assessment Program

PAUL WACHTER, M.D. ’61, AND DOROTHY WACHTER

“For medical students today, the explosion of knowledge in the basic sciences may make it hard to focus on looking at the patient as a person — taking a careful history, doing a thorough physical examination, and all the old-fashioned interactions that are so critical to the doctor-patient relationship and delivering excellent care. If anything needs support within the medical school curriculum, it is these very basic clinical skills.

“Einstein gave me an education in basic science and clinical skills second to none. So when my wife, Dorothy, and I learned of the plans for a new clinical skills center at Einstein, we were thrilled at the opportunity to support it. To me, clinical skills are the essence of a physician’s work, and I find it satisfying and fulfilling to be able to help nurture those skills in tomorrow’s physicians.”

Paul Wachter, M.D., is a psychiatrist in private practice in San Mateo, CA. He is the founder/director of the psychiatric residency program at San Mateo Community Mental Health Services.
A BRILLIANT BUILDING ILLUMINATES OUR FUTURE

In 2001, renowned investment fund manager Michael F. Price made what was, at the time, the largest commitment in the history of the College of Medicine — $25 million — to help establish a state-of-the-art center for genetic and translational medicine at Einstein, which was formally dedicated this June.

“The vision of where medical education and research are heading at Einstein inspired me to help finance a center in which scientists use their discoveries to create new drug therapies, pursue cures, and establish diagnostic tools and treatments that will dramatically improve how medicine is practiced,” says Mr. Price, who is a member of the Einstein Board of Overseers and chair of its executive committee. “My family and I are thrilled that the center has opened, and we thank everyone involved for doing a terrific job. I continue to view my investment in Einstein as among the wisest decisions of my career.”
The Albert Einstein College of Medicine is an institution that has been close to my heart for many years. I am extremely proud of the College of Medicine’s brilliant researchers and am delighted to have had the opportunity to help provide a new home for scientific discoveries that may help put an end to many serious diseases that afflict humanity.

MuRiel Block

Well known for her philanthropic activities in the New York metropolitan area, Mrs. Block has been a longtime leading supporter of the College of Medicine, as was her late husband, Harold. Her extraordinary gift to Einstein totaled $21.7 million.
“You dream dreams and make them happen. And in building this center, we’re aspiring to the greatest nobility in humanity — investing in humanity.”

Richard M. Joel
President, Yeshiva University

The Jewel of the Einstein Campus

Taking Aim at the Most Important Health Problems

The five-story Price Center/Block Research Pavilion cost $220 million and occupies 223,000 square feet — making it the largest medical research facility to be constructed in the Bronx since Einstein opened in 1955. The building is located across Morris Park Avenue from the Belfer and Forchheimer buildings on land that the College of Medicine has leased from Jacobi Medical Center.

The Price Center/Block Research Pavilion offers research space to 40 scientific investigators and their research teams, who will be targeting some of the most important health problems confronting society. Their research programs include the following:

**Cellular transplantation and gene therapy** will look for potential cures for cancer, liver disease, diabetes, cardiovascular disease, and brain disorders.

**Genetics and the biology of cancer** will explore the genetic mechanisms underlying metastasis and angiogenesis in cancer.

**Infectious diseases** will develop improved treatments for tuberculosis, malaria, HIV/AIDS, and potential bioterrorism agents.

**Human genetics** will study the genetic changes that make us susceptible to infectious diseases, psychiatric illness, heart disease, autism, aging, birth defects, and other conditions.

The success of these research programs will depend on the talent and expertise of the people who guide them. In this regard, the Price Center/Block Research Pavilion has already helped Einstein retain its leading scientific investigators and recruit others from around the country and the world.

On the following pages, four scientists in the Price Center/Block Research Pavilion describe what it means to work in the technologically sophisticated yet welcoming environment of this amazing new facility.

Ethel LeFrak, a longtime member of Einstein’s National Women’s Division, has made a generous $3 million gift in support of the Price Center/Block Research Pavilion. In appreciation, the College of Medicine has named the center’s auditorium the Ethel and Samuel J. LeFrak Auditorium in honor of Mrs. LeFrak and her late husband.

“I am very pleased to support this wonderful research center,” says Mrs. LeFrak. “My husband would be thrilled to have his name associated with an auditorium where the world’s most brilliant scientists will share the latest ideas and information that will help solve society’s most serious health challenges.”

Ethel LeFrak

The success of these research programs will depend on the talent and expertise of the people who guide them. In this regard, the Price Center/Block Research Pavilion has already helped Einstein retain its leading scientific investigators and recruit others from around the country and the world.

On the following pages, four scientists in the Price Center/Block Research Pavilion describe what it means to work in the technologically sophisticated yet welcoming environment of this amazing new facility.

“Cellular transplantation and gene therapy” will look for potential cures for cancer, liver disease, diabetes, cardiovascular disease, and brain disorders.

**Genetics and the biology of cancer** will explore the genetic mechanisms underlying metastasis and angiogenesis in cancer.

**Infectious diseases** will develop improved treatments for tuberculosis, malaria, HIV/AIDS, and potential bioterrorism agents.

**Human genetics** will study the genetic changes that make us susceptible to infectious diseases, psychiatric illness, heart disease, autism, aging, birth defects, and other conditions.

The success of these research programs will depend on the talent and expertise of the people who guide them. In this regard, the Price Center/Block Research Pavilion has already helped Einstein retain its leading scientific investigators and recruit others from around the country and the world.

On the following pages, four scientists in the Price Center/Block Research Pavilion describe what it means to work in the technologically sophisticated yet welcoming environment of this amazing new facility.
Collaborating to Cultivate Medical Breakthroughs

“The really exciting thing about this building is what it will do for scientific collaboration here at Einstein. Generally speaking, communication among basic scientists and clinical scientists occurs all too rarely and sporadically. Now, basic scientists and clinicians will be rubbing shoulders in a building that was specifically designed to encourage interactions and the sharing of ideas.

“Einstein already has an enviable reputation as a place where cooperation rather than competition is the norm, and the Price Center/Block Research Pavilion should make this collaborative culture an even stronger force on campus. People here will have the opportunity to cooperate not only with scientists in related fields but with those from areas that they’d normally consider quite distant.

“By emphasizing scientific cooperation, the Price Center/Block Research Pavilion is perfectly in sync with the way much of biomedical research is now being conducted — through interdisciplinary programs that combine biology with mathematics, computer technology, and other hard sciences. For example, my work in evolutionary and developmental biology involves several projects, each dependent on a diverse group of researchers contributing their expertise. Such collaborations will catalyze the breakthroughs that are sure to occur within these walls.”

AVIV BERGMAN, PH.D.
Professor and Chair, Department of Systems & Computational Biology, and Professor, Departments of Pathology and Neuroscience
Clever Design Encourages Flow of Ideas

“One thing that strikes you as you walk through the Price Center/Block Research Pavilion is how cleverly it was designed to encourage interaction. You just know, for example, that lunchtime is going to be an amazingly productive time for exchanging ideas, since the lunch area is located at the center of each floor of the building. Plus, on each floor, the computational researchers are juxtaposed to the molecular biologists. Whoever came up with these plans was really thinking. In addition, just the fact that the Price Center/Block Research Pavilion allows us to augment our current excellent faculty with a new group of great recruits is going to be valuable.

“These people will be entering what should be a very creative atmosphere that will only enhance their contributions to medical research. I predict that after a year of bringing in visiting speakers to give seminars in the Price Center/Block Research Pavilion the word will get out. Einstein will gain the recognition it deserves as a top-tier research institution ready to compete with anyone. This is going to be fun to watch.”

JOHN OREALLY, M.D., B.CH., PH.D.
Director of the Center for Epigenomics and Associate Professor, Departments of Genetics and Medicine

Susan and Benjamin Winter have made a generous gift in support of the Price Center/Block Research Pavilion at Einstein. The main lobby of the new facility has been named in their honor.

SUSAN AND BENJAMIN WINTER

“Einstein is doing cutting-edge research in diabetes, a growing epidemic in this country and a particular interest of ours. We made this commitment after meeting with Dean Spiegel, a diabetes expert in his own right. In addition, we were enormously impressed by the work being done by Dr. Jeffrey Pessin, one of the extraordinary new scientists recruited by Einstein, and by Dr. Norman Fleischer, a renowned endocrinologist. They and their colleagues are making every effort to overcome diabetes and save lives.”
Novel Facilities Will Yield Insights into Diabetes

“For me, one of the main attractions for relocating to Einstein from SUNY–Stony Brook was the opportunity to work in the Price Center/Block Research Pavilion. This building offers diabetes researchers state-of-the-art facilities that will allow us to expand our efforts in many directions that we could not otherwise have pursued.

“For example, we were able to create a novel research resource — the metabolomic core — for measuring pathophysiologic metabolites involved in obesity, insulin resistance, and diabetes. This core is one of only a handful of such facilities in the world and is crucial for developing new diagnostic indicators and for aiding our research into metabolic disorders.

“The addition of these modern laboratories to Einstein’s existing facilities is already helping us attract outstanding new faculty scientists, fellows, and students to our diabetes center. Being able to work in this building will help them compete for federal research funds as well as for grants from private funding agencies such as the Juvenile Diabetes Research Foundation and the American Diabetes Association.

“We are very excited at the prospect of pursuing diabetes research in these fantastic new facilities. The Price Center/Block Research Pavilion will undoubtedly help us in our efforts to understand the metabolic pathways that underlie diabetes and to translate those findings into better treatments.”

JEFFREY E. PESSIN, PH.D.
A key attraction of Einstein was the strength of its investigators in epigenetics and bioinformatics — right there with us in this new building — who can help us to analyze and manage this huge amount of data and to further refine our techniques."

SIMON DANIEL SPIVACK, M.D., M.P.H.

"Last year, when considering moving here from the New York State Department of Health’s Wadsworth Center, I realized that Einstein — and the Price Center/Block Research Pavilion in particular — was the perfect fit.

“My specialty is pulmonary medicine, and a key goal of our laboratory is to develop noninvasive strategies for identifying people at especially high risk for lung cancer. One of our approaches involves analyzing DNA in exhaled breath, looking for modifications known as biomarkers that serve as indicators to pinpoint individuals at high risk for disease.

“The silencing of certain genes through cytosine methylation — also known as epigenetic modulation — is now recognized as playing a crucial role in the development of lung cancer and many other types of cancer. After devising a way to precisely annotate the cytosine methylations within DNA sequences, we found ourselves inundated with numerous inter-individual differences in methylation patterns — differences not always explainable by people’s tobacco exposure.

“So a key attraction of Einstein was the strength of its investigators in epigenetics and bioinformatics — right there with us in this new building — who can help us to analyze and manage this huge amount of data and to further refine our techniques. And, of course, the spectacular space offered to us was also a major draw.”

SIMON DANIEL SPIVACK, M.D., M.P.H.
Chief, Division of Pulmonary Medicine, and Associate Professor, Department of Medicine
The Men’s Division

The Men’s Division of the Albert Einstein College of Medicine was formed in 1961 by a group of business leaders committed to advancing research and educational programs at the College of Medicine. In June 2008, the Men’s Division completed its $5 million fund-raising effort to establish a wing of research laboratories in the Price Center/Block Research Pavilion. The Men’s Division wing is located on the first floor and is dedicated to research involving stem cells and regenerative medicine.

Pictured at right: Leaders of the Men’s Division with Dean Allen M. Spiegel (third from left) at the formal dedication of the Price Center/Block Research Pavilion on June 12, 2008.

The National Women’s Division

The National Women’s Division of the Albert Einstein College of Medicine raised $5 million to establish a wing of laboratories in the Price Center/Block Research Pavilion devoted to women’s health and curing cancers that affect women.

Close to this wing, on the building’s second floor, wall plaques signify two other fund-raising projects sponsored by the Women’s Division: “50 for 50” involves 50 women contributing $50,000 each toward the purchase of technology to support the work of investigators in the Price Center/Block Research Pavilion, and the Wall of the Future displays the names of children whose parents and grandparents have donated $1,000 to honor the first generation that will directly benefit from the medical advances expected to flow from this new facility.

Pictured at right: Women’s Division leaders with honorees at the group’s 2008 Spirit of Achievement fund-raising event.

“All of us in the Men’s Division are passionate about Einstein and its mission to transform human health. The new Price Center/Block Research Pavilion gives Einstein’s brilliant scientists the best environment and the latest technology to help them understand and cure diseases like cancer and diabetes. It’s the cornerstone for the continued growth of this great institution.”

“Nothing is more important than helping to eradicate disease — we owe it to our children and grandchildren. The National Women’s Division is extremely proud to be a part of that effort at Einstein. By raising $5 million, we have been able to provide state-of-the-art equipment and facilities for the dedicated researchers at the Price Center/Block Research Pavilion who are working to cure all the devastating cancers that affect women.”
Marilyn and Stanley M. Katz grew up in the Bronx, not far from what is now the College of Medicine’s Jack and Pearl Resnick Campus, which is named for Marilyn Katz’s parents. Marilyn Katz’s sister, Susan Resnick Fisher (also a supporter of Einstein), died of a brain tumor in 1993 at age 50. Mrs. Katz decided to honor her sister’s memory by supporting efforts at Einstein to find cures for cancer. In 1998, Mrs. Katz became the founding chair of the Cancer Research Advisory Board of the Albert Einstein Cancer Center.

Marilyn Katz announced the new $7 million gift to the cancer center in February 2008, at a luncheon co-sponsored by Einstein and Susan G. Komen for the Cure. “I am delighted that Stan and I have the opportunity to help initiate this new program at Einstein,” said Mrs. Katz in her remarks. “We have such wonderful memories of growing up in the Bronx, so it’s especially gratifying to be able to give back to the community in this way.”

Marilyn and Stanley M. Katz have taken the slogan “Think globally, act locally” to heart. Their generous donation has created a program for preventing cancer among the people of the Bronx. Discoveries made possible by this program will contribute to cancer-prevention efforts nationwide.
Battling Cancer in the Bronx and Beyond

For many years, the Albert Einstein Cancer Center has fostered groundbreaking research at the College of Medicine. For example, its scientists were instrumental in developing Taxol, one of the most widely used drugs for treating cancer. As federal funding for biomedical research has diminished in recent years, the generosity of the College of Medicine’s philanthropic community has allowed the Albert Einstein Cancer Center to continue advancing toward its ultimate goal: eliminating cancer.

Thanks to a recent $7 million gift from Einstein Overseers Marilyn and Stanley M. Katz, longtime Benefactors of the College of Medicine, the cancer center has launched the Marilyn and Stanley M. Katz Comprehensive Cancer Prevention and Control Program. This innovative, community-based program may lead to new approaches for preventing cancer or detecting it at an early, curable stage. The program’s scientists will identify lifestyle and environmental factors that cause cancer among Bronx residents and carry out cancer-prevention initiatives focusing on smoking cessation, exercise, and healthy nutrition.

“The program created by Marilyn and Stanley Katz will greatly benefit the Bronx community while contributing to cancer-control efforts throughout the United States,” says I. David Goldman, M.D., Susan Resnick Fisher Professor and director of the Albert Einstein Cancer Center.

“We have such wonderful memories of growing up in the Bronx, so it’s especially gratifying to be able to give back to the community in this way.”

Marilyn Katz
“For people who are dying of T-cell leukemia and other T-cell cancers, we’re very hopeful that the promising clinical testing of Forodesine will lead to a once-a-day pill that will cure their cancer while causing no side effects.”

Vern Schramm, Ph.D., Professor and Ruth Merns Chair of Biochemistry

**CLINICAL TRIALS OF PROMISING THERAPIES**

The researchers of the Albert Einstein Cancer Center are working to find new therapies for combating human cancers. Recently, several of these scientists have developed agents with great potential for helping cancer patients.

**Vern Schramm, Ph.D.,** Ruth Merns Chair of Biochemistry at Einstein, studies the “transition state” of enzymes — the brief (one-tenth of one-trillionth of a second) period in which a substrate is converted to a different chemical at an enzyme’s catalytic site.

Dr. Schramm focuses on enzymes that are critical for the survival of cancer cells and for the immune system. After learning the precise picture of the transition state of such an enzyme, he can design a drug that binds much more tightly to this enzyme than its natural substrate — “locking up” the enzyme and preventing it from fueling cancer.

Dr. Schramm has used this method to develop several enzyme inhibitors. Forodesine, which blocks an enzyme that triggers T-cell malignancies, was licensed to BioCryst Pharmaceuticals, which reported positive results from its phase I/II clinical study treating T-cell lymphoma. A second inhibitor shows promise against autoimmune diseases, including psoriasis, multiple sclerosis, and rheumatoid arthritis. A third inhibitor works against cancers of the head and neck, prostate, and lung.

**Arturo Casadevall, M.D., Ph.D.,** Leo and Julia Forchheimer Chair of Microbiology & Immunology at Einstein, didn’t set out to cure melanoma. He studies fungi and the diseases they cause. But then his lab developed an antibody that not only targets melanin in fungi but also recognizes human melanin, the pigment made by the rapidly dividing cells that form melanoma tumors.

Dr. Casadevall and his colleague Ekaterina Dadachova, Ph.D., associate professor of nuclear medicine at Einstein, realized this antibody might help against melanoma if they “piggybacked” radiation-emitting isotopes onto the antibodies. Impressively, melanoma tumors in mice stopped growing the day they received the therapy.

Einstein licensed this technology to Pain Therapeutics, Inc., which recently announced positive results of a phase I clinical trial. The antibodies successfully bound to tumors in 12 patients with advanced melanoma, with no serious adverse effects. Melanoma patients in an upcoming trial will receive higher doses of the radiolabeled antibodies.
Outstanding Researcher Named Olnick Faculty Scholar

Ekaterina Dadachova, Ph.D., associate professor in the departments of nuclear medicine and of microbiology & immunology, has been named the first Sylvia and Robert S. Olnick Faculty Scholar in Cancer Research at Einstein. Dr. Dadachova is a pioneer in the use of radioimmunotherapy to treat cancer and infectious diseases.

Radioimmunotherapy involves attaching radioactive isotopes to antibodies that latch on to proteins associated with cancer cells or other targeted cells. Once the antibodies have attached to their targets, the isotopes emit radiation that kills the cells. In a recent clinical trial, Dr. Dadachova’s radioimmunotherapy technique for melanoma (developed in partnership with Einstein’s Dr. Arturo Casadevall) has shown promise in treating patients afflicted with this cancer.

Mrs. Sylvia Olnick, a longtime supporter of Einstein, made a gift of $1 million to establish this endowed faculty position. “My parents impressed upon me that the ability to give is a sacred responsibility, not to be taken lightly,” said Mrs. Olnick. She and her late husband, Robert, who died of melanoma in 1986, also established a professorial chair in neuroscience at the College of Medicine.

“My husband believed in the importance of giving back. He also believed, as I do, in the mission of the Albert Einstein College of Medicine. Both of us were extremely impressed by the scope of medical research at Einstein and by the excellence of its faculty.”

The Breast Cancer Research Foundation has given $225,000 to support breast cancer research being conducted by Rachel Hazan, Ph.D.

The foundation has also given $249,910 this year to support breast cancer research under the direction of Thomas E. Rohan, M.D., Ph.D.

The Damon Runyon Cancer Research Foundation has donated $100,000 to support the research of Peter D. Cole, M.D., which focuses on acute lymphoblastic leukemia in children.

The Lymphoma Research Foundation has pledged $105,000 over two years to support the lymphoma research of Irina Velichutina, Ph.D.
National Cancer Institute Endorses Einstein Research

The Albert Einstein Cancer Center, established by the National Cancer Institute (NCI) in 1972, is among the first such centers of its kind. The continuing excellence of the center was affirmed in 2008, when the NCI awarded it a five-year, $20 million grant renewal — a decision that followed rigorous peer review by nationally recognized experts in cancer research. As Einstein Executive Dean Edward R. Burns, M.D., points out, the NCI grant renewal “gives Einstein entry into a very exclusive club of top-flight investigative academic institutions.”

One of only four NCI-designated cancer centers in New York City, the Albert Einstein Cancer Center brings together 148 basic scientists, physicians, and clinical investigators, including the three newly recruited researchers whose work is described on the next page.

The center gives Einstein researchers access to sophisticated instruments and technical expertise that would be too costly to set up in each researcher’s lab. It also offers pilot funding for scientists to test novel ideas that don’t yet have enough data to support a major grant application.

The College of Medicine licenses its promising new cancer therapies to biotechnology companies with the resources to test them in clinical trials. Once such therapies receive approval from the U.S. Food and Drug Administration, Einstein receives royalties from companies that market them.

JANET BURROS MEMORIAL FOUNDATION

The Janet Burros Memorial Foundation has generously donated $300,000 to the College of Medicine to advance ovarian cancer research. This gift will support major core research facilities that play a vital role in providing new technologies and specialized equipment that are essential to ovarian cancer research activities at the Albert Einstein Cancer Center.

“After meeting Dean Spiegel, Dr. I. David Goldman, and some of the very talented faculty members at the Albert Einstein Cancer Center, we were impressed with the vision and strategic research plan of the College of Medicine,” notes Mara Burros Sandler, who, along with her husband, Ricky Sandler, and her brother, Chet Burros, serves as a trustee of the foundation. “We’re convinced that Einstein’s dedicated scientists have the potential to make important contributions in the fight against this terrible disease.”
COMBATING WOMEN’S CANCERS

The Albert Einstein Cancer Center has a vigorous research program that investigates cancers that primarily or uniquely affect women. Three new investigators have strengthened the cancer center’s efforts to understand and eradicate these cancers.

Harriet O. Smith, M.D., recently found that the protein GPR30, when present in high levels in endometrial cancers, predicts a much lower chance of survival. More recently, she identified the same protein in aggressive ovarian cancers. Using cell and animal models, she and her colleagues hope to discover how GPR30 and other factors stimulate tumor growth and then find drugs that can block the spread of these cancers. Dr. Smith worked at Einstein in the 1990s and returned here this summer from the University of New Mexico Health Sciences Center. “I was drawn back to Einstein by the spirit, the compassion, and the vision that seem to permeate this institution and its investigators,” she says.

Claudia Gravekamp, Ph.D., is developing vaccines for metastatic breast cancer. Her laboratory has already made cancer vaccines that are highly effective against metastatic breast cancer in young mice. Cancer vaccines work by revving up the immune system to attack tumor cells. But more than half of all cancer patients are 65 and over, meaning their immune response is muted. “So it’s not surprising that vaccines now being tested are not so effective, because they were never optimized for old age,” says Dr. Gravekamp. She is testing breast cancer vaccines in young and old mice, developing strategies to make the vaccines more effective at older ages. Dr. Gravekamp was recruited from the California Pacific Medical Research Institute in San Francisco.

Antonio Di Cristofano, Ph.D., studies a cellular signaling pathway that misfires in breast and endometrial cancer and several other types of cancer. “Using genetically engineered mice, we’re identifying the sequence of biochemical events by which this pathway transforms a normal cell into a cancer cell,” says Dr. Di Cristofano. “Once we know the steps along this pathway, and how they are interconnected with other signaling cascades that are altered in cancer, we may be able to specifically target them and prevent the progression to cancer.” Dr. Di Cristofano cites the College of Medicine’s “very collaborative and open environment” and its “breadth of scientific excellence” as major incentives for moving his lab here from the Fox Chase Cancer Center in Philadelphia.

“Once we know the steps along this pathway, we may be able to specifically target them and prevent the progression to cancer.”
Antonio Di Cristofano, Ph.D.
Departments of Developmental and Molecular Biology and Obstetrics & Gynecology and Women’s Health
HEALING THE PSYCHE AND SPIRIT

A cancer diagnosis triggers a host of emotions, including shock, fear, and helplessness. But all too often, these inevitable psychosocial effects of the disease receive little attention, particularly in medically underserved areas such as the Bronx.

To ensure that cancer patients in the county get appropriate care for both mind and body, the Psychosocial Oncology Program at Einstein and Montefiore Medical Center offers free activities and services ranging from yoga and dance classes to individual counseling and support groups.

Sylvia Williams, a Bronx resident treated for breast cancer a year ago, is one of hundreds of patients who have taken advantage of the Psychosocial Oncology Program. Feeling stressed by fear that her cancer might recur, she enrolled in yoga and meditation classes — activities she had never tried before. Now, she attends as often as possible.

“The yoga and meditation classes help me relax,” says Ms. Williams. “They remind me that I’m a survivor and encourage me to take control of my life.”

Ms. Williams says she also plans to participate in a program scheduled to begin in 2009: the Breast Oncology Living Daily (BOLD) Program, specifically designed for breast cancer patients and their loved ones. The BOLD program offers a wide variety of classes, including dance fitness, nutrition education, music inspiration, crocheting, jewelry making, and genetics & cancer.

“In the future, I would love to start an integrative oncology program, combining complementary and conventional medicine,” says Alyson B. Moadel, Ph.D., associate professor of medicine and of epidemiology & population health at Einstein, who directs the Psychosocial Oncology Program. “Ideally, every patient who comes in for chemotherapy or radiation treatment should also be able to get mind-body therapies.”

A clinician as well as a researcher, Dr. Moadel has been awarded grants from the National Cancer Institute and other organizations to study the effects of quality-of-life interventions on cancer patients.
"When I was seven, my mother was diagnosed with breast cancer and died 10 years later. Attending a support group greatly helped to ease her emotional and physical pain. That’s why I’m developing programs to support the mind, body, and spirit of all those touched by cancer."

ALYSON B. MOADEL, PH.D.

ENTERTAINMENT INDUSTRY FOUNDATION

The Entertainment Industry Foundation has made a $105,000 grant in support of the Albert Einstein Cancer Center’s Psychosocial Oncology Program. Under the direction of Dr. Alyson Moadel, the program provides support, counseling, and complementary medicine services for cancer patients living in the Bronx. This grant is based on funds raised from the 2007 EIF Revlon Walk/Run for Women, which raises money for research into cancers that affect women. Einstein has been a beneficiary of the Walk/Run for two consecutive years (2007 and 2008) thanks to the efforts of a participant in the Einstein program.
Early Detection Can Change Young Lives

When Malachi began to exhibit signs of autism as a toddler, his mother immediately brought him to CERC. She knew that early evaluation and treatment were important, since her daughter was already being treated at CERC for a mild form of autism known as Asperger’s syndrome. Now almost four, Malachi receives treatment at preschool and in a weekly language–social interaction group at CERC.

Kids with autism have a variety of developmental difficulties: trouble with social interactions and communication, a limited range of interests, and repetitive, stereotyped behaviors — all typically starting before age three. Autism is called a spectrum disorder because its impairments can vary widely in severity from one individual to another.

Diagnoses of autism spectrum disorders have increased nearly tenfold over the past decade. Fortunately, the early intervention offered by CERC may prevent autism from worsening and even help the child develop relatively normally.
Seeking Answers at CERC

While reading this article, why not try turning on the television, eavesdropping on a conversation and, for good measure, counting backward from 100 by sevens? Having trouble concentrating?

Now you have an inkling of what life is like for the 5 to 7 percent of the population with attention deficit hyperactivity disorder, or ADHD.

“It’s called attention deficit disorder, but what really happens is that they pay attention to too much,” explains Alec B. Cecil, Ed.D., a clinical psychologist with Einstein’s Children’s Evaluation and Rehabilitation Center (CERC). As a result, kids with ADHD flit from one activity to another, accomplishing little. They also tend to be forgetful, act impulsively, and have trouble planning ahead — severe handicaps for school and for life in general. That’s where CERC — one of the nation’s largest and most renowned facilities of its kind — comes in.

CERC is a special place for helping people with ADHD, autism, and other serious developmental disabilities. Each year it serves about 7,000 children and their families and trains some 1,000 health professionals.

More than a half-century old, CERC is a rare facility that offers comprehensive ADHD services. They range from thorough evaluations to carefully tailored treatment programs that usually combine cognitive and behavioral counseling, psychoeducational therapy, and medication management. There is also an Adult Literacy Program offering individualized coaching to people who have trouble with reading, writing, or math — the only such program in New York City.

“"We couldn’t be more pleased at the outpouring of support for cutting-edge clinical research at CERC. Millions of children with autism and other developmental disorders, and their families, may potentially benefit from this investment."

Bambi Felberbaum, President, National Women’s Division

The National Women’s Division of the Albert Einstein College of Medicine is conducting a fund-raising initiative that so far has raised more than $2 million to establish a clinical research program at CERC.
To appreciate the impact of illiteracy and other learning disabilities, consider this: 42 percent of families headed by a learning-disabled adult live below the federal poverty level, compared with 16 percent of the general population. In addition, people at the lowest levels of literacy generally live shorter and less-healthy lives. And then there’s the psychological toll.

“Most adults who can’t read have awful self-esteem — they feel terribly ashamed and embarrassed,” says Mary S. Kelly, Ph.D., director of CERC’s Fisher Landau Center for the Treatment of Learning Disabilities and the center’s Adult Literacy Program (pictured at left). “They often have a great deal of trouble maintaining relationships, because they’re hiding a big part of who they are. Some don’t even tell their spouses they can’t read.”

The Adult Literacy Program at CERC helps about 300 people each year. They may have trouble telling “Walk” from “Don’t Walk,” understanding the label on a medicine bottle, or reading a bedtime story to a child. Clients range in age from 18 to 72, with an average age of 34.

“For individuals who can’t read at all, we start by immediately teaching them sight words — ‘walk,’ ‘price,’ ‘sale,’ ‘caution,’ and other words crucial for daily living,” says Dr. Kelly. “We are the only program in New York City that provides the one-on-one coaching that is essential for teaching grownups to read.”

An estimated 1.5 to 3 million adults in New York City need literacy services, while fewer than 60,000 receive them. “CERC has the expertise,” says Dr. Kelly, “but we need the support that will allow us to help more New Yorkers learn to read.”

“I was proud to establish the Fisher Landau Center for the Treatment of Learning Disabilities at Einstein in 1997. Having been diagnosed with dyslexia myself, later in life, it was very important to me that adults be included in the program.”

**EMILY FISHER LANDAU**
Einstein Overseer
SPURRING INNOVATION

“With intensive treatment, many children with ADHD do relatively well,” says Dr. Cecil, who specializes in treating adolescents with ADHD. “Still, they are more likely to have problems with school, with relationships, with holding jobs.”

In addition to managing his young patients, Dr. Cecil also manages their parents’ expectations. “Treating ADHD involves a lot of work over a long period of time to see gradual progression,” he says. “That’s why I’m always looking for promising new answers that can only arise from additional research.”

Each year, CERC’s staff of 150 physicians, psychologists, speech therapists, audiologists, social workers, occupational and physical therapists, and other specialists works together to help about 7,000 children and adolescents as well as some adults. Based on the results of their evaluation, clients are assigned to one of nine different CERC units for treatment and follow-up care.

Two facilities — the Early Childhood Center, on the Einstein campus, and the Center for Babies, Toddlers, and Families, at 1521 Jarrett Place in the Bronx — offer services for young children with developmental or behavioral problems. Both facilities also offer help to the parents: psychiatric services, including individual psychotherapy, are available to parents struggling with depression or ongoing traumas such as domestic violence.

Other services provided by CERC include a psychoeducational treatment program for school-age children; a clinic for children who suffer from seizures; a facility for clients who require ongoing medication for behavioral management; a clinic for children with special nutrition needs; a dental clinic; an ophthalmology facility; a low-birthweight follow-up program; and school services for adolescents who have learning or developmental disabilities such as ADHD and associated social behavioral problems.

“CERC has a well-deserved reputation for clinical expertise and training programs that have produced the lion’s share of national leaders in the field,” says Robert W. Marion, M.D., director of CERC and the Ruth L. Gottesman Professor in Developmental Pediatrics. “Unfortunately, research is the one area where we’ve been relatively weak.” But that’s about to change.

Under Dr. Marion’s leadership, CERC is planning an ambitious research program in which its clinicians will partner with Einstein’s scientists. The goal: to spur new collaborations and translate the resulting discoveries into new ways of diagnosing, treating, and preventing developmental disabilities.
"When treating people with ADHD, we have no clear way to decide when to use medication or which particular drug to choose. We need a research program that can assess the effectiveness of drugs and other interventions used to treat this disorder."

— NORMAN M. BRIER, PH.D.
Director, Adolescent Unit of CERC, and Professor, Departments of Pediatrics and Psychiatry and Behavioral Sciences

PURSUING A POTENTIAL ADHD TREATMENT

Dr. Cecil, for example, has no shortage of research topics he’d like to pursue. One involves the value of neurofeedback, a promising but underscrutinized therapy for ADHD.

A type of biofeedback, neurofeedback is based on the finding that most individuals with ADHD have abnormally low brainwave activity in their frontal lobes. The therapy gives them real-time feedback about their brainwaves and teaches them to use that information to control their frontal-lobe activity. Several small studies suggest that neurofeedback training can eliminate many symptoms associated with ADHD, giving rise to a thriving business in which companies market costly neurofeedback software for use at home.

Neurofeedback could potentially replace Ritalin and other stimulant drugs that so many kids with ADHD now depend on. But studies that could firmly show whether neurofeedback actually helps are badly needed. “Einstein is the ideal place to do the research that would provide the answer,” says Dr. Cecil. “A clinical trial of neurofeedback would also offer a great opportunity for CERC to collaborate with Einstein’s experts in neurology and cognitive science.”

Because they’re so easily distracted, people with ADHD tend to have more traffic accidents than the rest of the population. So CERC’s ADHD specialists would like to test therapies that might reduce the accident risk for these individuals. The experience of Doug from Long Island illustrates the need to find better treatments.

“Doug was ashamed that he couldn’t drive, but he knew he was a danger to himself and others behind the wheel,” says his therapist, Norman Brier, Ph.D., director of CERC’s Adolescent Unit. “We found someone who gives driving lessons to disabled people, but he had never given a lesson to an ADHD-disabled person before. Doug went for a lesson, but the instructor wouldn’t shut up. All the while, he’s talking to Doug and distracting him.”

It would be comical if it weren’t such a serious issue. A possible way to help drivers with ADHD, says Dr. Brier, might involve adapting the systems used to train air traffic controllers, who must learn how to manage their way through an onslaught of information.

More generally, there’s a pressing need to take a closer look at the most commonly used ADHD therapies. “We need to tease out which particular aspect is helpful — the medications, the family work, the group therapy, the consultations with schools and teachers — and then find what works best for different types of patients,” says Dr. Cecil.
CERC is planning a major research program in autism — a field where Einstein has had a huge impact over the years. Einstein’s investigators, particularly Isabelle Rapin, M.D., were among the first to shed light on the language and behavioral regression observed in young children with autism and to report on the positive effect of early intervention — with its emphasis on improving communication skills — to ameliorate autistic behaviors.

Today, CERC is highly regarded for its autism services, most notably the RELATE (Rehabilitation, Evaluation, and Learning for Autistic Infants and Toddlers at Einstein) program. CERC also offers an unusual dental program for children and adults with autism and other developmental problems.

“Everybody needs dental care, but if you have autism, you’re not going to sit still and cooperate,” says Dr. Robert Marion, CERC’s director. “We are the only place in the city that does conscious sedation for individuals with developmental disabilities, which we can do right here in our offices.”

While scientists have made significant strides in understanding autism, the disease largely remains a mystery. “We don’t know what causes it — whether, for example, it’s mainly genetic in origin or not — and we really don’t know how best to treat it,” explains Dr. Marion. “What helps some individuals does not help others.”

He notes that a lot of professionals are capitalizing on the scientific ignorance surrounding autism by offering “all sorts of untested therapies” to those willing and able to pay. “We need to do the scientifically rigorous research that can inform people about what works for autistic kids and what doesn’t,” says Dr. Marion.

“Autism: Continuing a Legacy of Innovation

“What we do for kids with ADHD seems to help. But we need to tease out which particular aspect is helpful — the medications, the family work, the group therapy, the consultations with schools and teachers — and then find what works best for different types of patients.”

ALEC B. CECIL, ED.D., CERC Clinical Psychologist and Assistant Clinical Professor, Department of Pediatrics
Rose Spata, a longtime resident of the Bronx, was diagnosed as being prediabetic — and therefore at high risk for developing type 2 diabetes. Her doctor referred Rose to Einstein, where she was enrolled in the Diabetes Prevention Program. It was carried out at Einstein and other locations across the U.S. with the aim of finding effective strategies for preventing type 2 diabetes in people who are at risk for the disease. While participating in the program, Rose received intensive training to help her change her diet and get more exercise.

The prevention program was ended early because its results were so clear: lifestyle changes and diabetes medication can both significantly reduce the risk of developing type 2 diabetes.

Since participating in the prevention study, Rose has remained diabetes-free. She still watches her diet closely and exercises regularly by taking long walks with her daughter. For her, the take-home message is simple: “The most important thing is to make sure that you take care of yourself.”
Taking Aim at an Epidemic

People living in the Bronx have disproportionately high rates of many chronic health problems. One of them — obesity — all too often causes Bronx residents to develop diabetes, a growing public health threat both locally and across the nation.

For more than 30 years, researchers at Einstein’s Diabetes Research and Training Center (DRTC) have worked to combat diabetes and its disastrous complications. Created in 1971 with 22 scientists and less than $1 million in funding, the DRTC now has nearly 70 investigators with $30 million in diabetes-related grant support from the NIH and other public and private agencies.

Jeffrey Pessin, Ph.D., took over as DRTC director in January 2008, following the distinguished 25-year tenure of Norman Fleischer, M.D. “The Albert Einstein College of Medicine provides an incredible environment in which to do diabetes research,” says Dr. Pessin, an internationally recognized diabetes expert recruited to Einstein from SUNY–Stony Brook.

“The situation regarding diabetes is worrisome,” says Dr. Pessin, who points to findings from a nationwide federal survey released this October. The survey found that the rate of new diabetes cases in the U.S. has nearly doubled in the past 10 years. Ninety percent of diabetes cases involve type 2 diabetes, which primarily affects adults.

“I’m hopeful that Einstein’s DRTC can help reverse this trend,” says Dr. Pessin. “Once we understand the metabolic pathways underlying diabetes, we can translate those findings into better treatments for the disease and — even more important — therapies to keep people from developing diabetes.”

“Einstein’s Diabetes Research and Training Center has been highly successful. We’ve recruited an outstanding group of scientists whose research efforts are making a real difference in preventing and treating diabetes.”

NORMAN FLEISCHER, M.D., the Jacob and Jeanne E. Barkey Professor of Medicine and Former Director of the DRTC.
In a special honor last May, the National Institutes of Health awarded Einstein and Montefiore Medical Center one of their coveted Clinical and Translational Science Awards, totaling $22 million over five years. The grant supports the new Einstein-Montefiore Institute for Clinical & Translational Research.

“Translational medicine” is the concept — encouraged by the NIH in recent years — that new discoveries should be rapidly transferred from the laboratory to the clinic so that patients can benefit from them as soon as possible.

“Ideally, translational medicine functions as a two-way street, with laboratory findings leading to clinical benefits but also with information gained in the clinic feeding back into basic research,” says Harry Shamoon, M.D., associate dean for clinical & translational research at Einstein and director of the institute for clinical & translational research. “We have an exciting challenge ahead of us in enhancing the flow of information in both directions.”

Einstein and Montefiore have now become one of 38 academic health centers in the U.S. to have received a Clinical and Translational Science Award.

Thanks to this NIH grant, Einstein and Montefiore researchers can now intensify their long-standing collaborative programs in treating and preventing human diseases.

“We plan to use a portion of these funds to foster a wide range of new clinical research, such as expediting clinical trials in breast and colon cancer, developing advanced methods of treating congestive heart failure, and encouraging preventative programs in diabetes,” says Dr. Shamoon.

“Ideally, translational medicine functions as a two-way street, with laboratory findings leading to clinical benefits and with information gained in the clinic feeding back into basic research.”

Harry Shamoon, M.D., Associate Dean for Clinical & Translational Research and Professor, Department of Medicine
EARLIER DETECTION, BETTER THERAPY

The DRTC helps diabetes researchers like Einstein’s Daniel Thomas Stein, M.D., turn innovative ideas into new technologies.

Starting with a small DRTC pilot grant, Dr. Stein developed a highly sensitive technique for measuring C-peptide, a protein that reflects the amount of insulin produced by beta cells in the pancreas. He is now investigating whether his C-peptide test can serve as a noninvasive way to monitor the number of insulin-producing beta cells in the pancreas and their failure during the onset of type 2 diabetes.

“One of the profound mysteries in diabetes research is what goes wrong with beta cells as type 2 diabetes develops,” says Dr. Stein, associate professor in the department of medicine. “Ultimately the C-peptide assay may help identify people at risk for type 2 diabetes so that intensive lifestyle or drug interventions might ward off the disease.”

Several shared facilities, or “cores,” provide DRTC investigators with access to the latest technology:

• The “metabolomic” core provides equipment for analyzing the many chemicals produced during enzymatic reactions. This facility allows researchers to pinpoint the biochemical defects that occur in obesity, insulin resistance, and diabetes, and then to target those defects using highly specific therapies.

• Two cores, the flow cytometry and analytical imaging cores, support research into the immune system’s role in type 1 and type 2 diabetes and also allow scientists to study the movement and localization of proteins within cells.

• The animal physiology core allows for state-of-the-art metabolic studies of animals that develop diabetes and obesity, allowing researchers to assess the benefits and molecular mechanisms of specific therapies.

Not all DRTC cores emphasize basic research. Jill Patricia Crandall, M.D., co-directs the Clinical Research Facilitation Core, which has contributed to landmark clinical trials that have revealed new strategies for preventing and treating diabetes.

One of those trials, for example, showed that type 1 diabetes patients who carefully control the glucose level in their blood can dramatically reduce the risk of complications affecting their eyes, kidneys, and nerves. An ongoing trial is evaluating an inexpensive drug, salsalate, as a possible treatment for type 2 diabetes.

“Anything we discover that adds to our choices for helping people control their diabetes has a direct impact on the health of the Bronx,” says Jill Crandall, M.D., Co-director of the Diabetes Research and Training Center’s Clinical Research Facilitation Core and Associate Professor, Department of Medicine.
“Findings from this study may improve the way diabetes is treated in terms of reducing the risk of complications.”

MICHAEL A. BROWNLEE, M.D., the Anita and Jack Saltz Professor of Diabetes Research

PREVENTING DIABETIC COMPLICATIONS

Diabetes is a chronic and insidious disease. Over the years, abnormally high blood sugar levels can damage cells and wreak havoc with the body from head to toe.

Diabetes is the leading cause of blindness, kidney failure, and amputations in the U.S. (Amputations are the end result of diabetes-induced impaired blood flow and loss of feeling in the lower extremities, which can lead to severe ulcers and infections.) Having diabetes triples a person’s risk for a heart attack or stroke, more than doubles the risk of hearing loss, and increases the likelihood of depression. The disease can also impair sexual functioning for both men and women and lead to many other health problems, including liver disease and periodontal disease.

Unless better ways are found to ward off diabetic complications, the devastation from this disease seems likely to intensify: results of a study by the U.S. Centers for Disease Control and Prevention, announced last June, showed that the number of Americans who have diabetes has risen to 23.6 million people, or 8 percent of the population.

For Michael A. Brownlee, M.D., the Anita and Jack Saltz Professor of Diabetes Research at Einstein, finding strategies for preventing diabetic complications is not just a matter of professional interest: he himself has had type 1 diabetes from a young age. While personally free of complications so far, Dr. Brownlee notes that taking insulin to regulate glucose levels in the blood does not prevent problems in all type 1 diabetes patients.

Dr. Brownlee and his colleagues recently published findings that, he says, “may improve the way diabetes is treated in terms of reducing the risk of complications.”

For many years, diabetes therapy has focused on reducing a person’s “HbA1c level,” a number reflecting the average level of glucose (sugar) in the blood over an extended time (three months). Keeping one’s glucose within normal levels most of the time usually results in a low HbA1c value — and, it was assumed, a reduced risk for complications. But HbA1c readings don’t capture occasional, temporarily high levels of glucose — the kind that might follow a large meal, for example.

Dr. Brownlee’s team found that these blood glucose “spikes” may be clinically significant, since they alter cells’ DNA in ways that persist long after the glucose level has returned to normal. Those DNA changes keep tissue in a state of inflammation — an underlying cause of organ damage. Therefore, says Dr. Brownlee, “treatment strategies that minimize or prevent glucose spikes might help prevent the devastating complications of diabetes.”
Simple Measures But Tremendous Health Impact

Can seemingly promising measures against diabetes actually help the people most in need of them? The Prevention and Control Division of Einstein’s Diabetes Research and Training Center is addressing that important question.

Directed by Elizabeth A. Walker, Ph.D., the division carries out studies that can have a major impact on people living in poor Bronx communities, where access to care is limited and the prevalence of diabetes is high.

Recently, Dr. Walker and her colleagues found that regular phone calls from bilingual health educators were highly successful in prompting poor Bronx diabetes patients to go in for dilated eye exams. Such exams can help prevent serious retinal complications in people with diabetes.

Dr. Walker relates the story of one study participant: a Spanish-speaking man who told a health educator that he took his diabetes medication once a day. He said that the pill bottle’s label contained the word “twee-say,” but he didn’t know its meaning. The bilingual educator explained that the word — “twice” — meant he should actually be taking his pills twice a day rather than just once.

For Dr. Walker, this anecdote highlights the potential benefits that simple, low-cost interventions can have on public health. “If something as basic as a phone call can correct the amount of medication that someone is taking,” she says, “then the health payoff from such measures could be fantastic in terms of lowering rates of diabetes complications in the South Bronx.”

NIH PATHFINDER AWARD

Each year, the National Institutes of Health award grants to 10 scientists who are conducting especially promising research on type 1 diabetes — work with exceptional potential for improving the prevention and treatment of the disease and its complications. One of the award recipients for 2008 is Xingxing Zang, Ph.D., a new faculty member in Einstein’s Diabetes Research and Training Center. Dr. Zang will use the five-year, $1.5 million grant to continue research aimed at preventing type 1 diabetes. His work involves inhibiting the immune system’s T lymphocytes from destroying the insulin-producing cells of the pancreas.

“If something as basic as a phone call can correct the amount of medication someone takes, then the health payoff could be fantastic in terms of lowering rates of diabetes complications.”

ELIZABETH A. WALKER, PH.D., Professor, Departments of Medicine and Epidemiology & Population Health
THE LATE BLOOMER

The idea of becoming a doctor didn’t cross Olivia Nelson’s mind until a family friend, a physician, invited her to observe his obstetrical practice at Yale–New Haven Hospital. Several years out of college by then, Olivia (pictured above) had some catching up to do.

While taking premed classes at the University of Massachusetts, she worked as a personal care assistant. Next, she served as a volunteer in a Nicaraguan medical clinic, where she learned Spanish. After a yearlong stint as a health educator for kids with asthma at NYU’s Child Study Center, Olivia was ready to apply to medical school. Einstein was a natural choice.

“I wanted to use my Spanish-language skills and to work in primary care with an immigrant population,” she says. Receiving a Louis and Rachel Rudin Medical Scholarship sealed the deal.

Now in the Class of 2010 and immersed in third-year clinical rotations, Olivia has served on the board of the Global Health Club and conducted research in hematology. “I’m thinking about applying to the Clinical Research Training Program, or doing international research,” she says.
Educating Caring Physicians

Why does Einstein produce first-rate physicians and researchers? Because it starts with such top-notch applicants. Each and every student brings to Einstein a background rich in accomplishments and life experiences.

“Scholarships are crucially important in making Einstein competitive with other prestigious medical schools when it comes to attracting the best students,” says Stephen Graham Baum, M.D., senior associate dean for students at Einstein. “In addition, students with scholarship support can take extra time to train in basic or clinical research, or they may feel freer to pursue less-remunerative specialties such as primary care or to work in rural or underserved areas.

“We’re grateful for the generous scholarship support that our donors already provide our students,” says Dr. Baum. “But especially now, in this difficult economy, we’d like to be able to offer more help. Not only the students but our College of Medicine and our society would all benefit from supporting and training the best possible future physicians.”

This article profiles four recent or current students who have benefited from Einstein scholarships. They were well worth the investment.
The Service and Research Golding Scholarship has helped me to minimize my medical school debt so that I can follow my passion of working with underserved people. My wife is training to become a Lutheran minister, and she and I hope to work with an international organization such as Oxfam or Doctors Without Borders.”

Joel Bumol, Class of 2011

Joel Bumol remembers the day he became interested in global health and social justice. It was the morning of his SATs, but Joel’s attention was drawn to a New York Times obituary for Nkosi Johnson, a South African orphan who had contracted HIV at birth. Nkosi, who died at age 12, had been an outspoken critic of his government’s failure to address the AIDS epidemic.

“Suddenly, the SATs didn’t seem that important,” recalls Joel, who served as president of his college’s Justice Club, a student organization committed to promoting peace, justice, and human rights.

For Joel, choosing a medical school was relatively easy. “I found Einstein to have the strongest commitment to serving poor and marginalized populations,” he says.

Now a second-year medical student, Joel is pleased that so many Einstein classmates and faculty members share his concerns. He is aiming toward a primary-care career with an international aid organization, a decision made easier by generous support from the Samuel H. and Rachel Golding Distinguished Scholars Program.

Life Lessons from a 12-Year-Old Boy
Einstein Overseer Nathan Kahn and his wife, Sandra, made a gift of $225,000 to the College of Medicine that will improve medical education at Einstein in two important ways.

Einstein was high on his list when it came time to apply to medical school. The financial aid offered through the Samuel H. and Rachel Golding Distinguished Scholars Program was an added enticement. “I liked what Einstein offered — particularly the opportunities in social medicine and global health,” says Chris. “The College’s values were the values I was looking for, and I haven’t been disappointed.”

Einstein Overseer Nathan Kahn and his wife, Sandra, made a gift of $225,000 to the College of Medicine that will improve medical education at Einstein in two important ways.

The Kahns donated $175,000 this year toward the renovation of the third-floor lecture hall in the Forchheimer Medical Science Building. As a result, the lecture hall was transformed into a state-of-the-art learning environment in time for the arrival of the Class of 2012 last August.

The Kahns’ gift also included $50,000 to establish an endowed scholarship fund in memory of Marsha Goldstein Basson, M.D. ’89, who passed away in April after a valiant battle with pancreatic cancer. A noted diagnostic pathologist, Dr. Goldstein Basson cared deeply about the younger generation of physicians and scientists. The Dr. Marsha Goldstein Basson Memorial Scholarship Fund will enable future medical students to benefit from the Einstein education that this exceptional alumna both embodied and valued.

“I am indebted to Einstein for the financial aid provided to me, and I hope to reciprocate by practicing medicine in the Einstein tradition.”

Christopher Hawk, Class of 2011
"I was focused just on getting through medical school when I was attending Einstein," says Yvette Calderon, M.D., M.S., a 1990 Einstein graduate.

"But when I started working in emergency medicine at Jacobi Medical Center and wanted to make our interventions more effective, I realized I didn’t know how to create studies or attract funding."

For Dr. Calderon, who was born in Puerto Rico and raised on Manhattan’s Lower East Side, a master’s degree from Einstein’s Clinical Research Training Program would provide the answers — but how to pay for it? With CRTP’s help, she obtained a fellowship from Einstein’s Hispanic Center of Excellence. Problem solved, and a distinguished career launched.

Dr. Calderon now directs adult urgent care at Jacobi and serves Einstein as associate professor of emergency medicine, assistant professor of pediatrics, and assistant dean of the College of Medicine’s office of diversity enhancement. In 2008, the Society of Academic Emergency Medicine awarded her the Outstanding Academician Award for her clinical research achievements.

“Since graduating from the Clinical Research Training Program in 2005, I’ve published three articles and presented my clinical findings nationally and internationally. I’m grateful to Einstein’s Hispanic Center of Excellence for helping me pay for this program that has done so much to change my life and career.”

YVETTE CALDERON, M.D. ’90

The Rudin family has a long and distinguished tradition of philanthropy and public service in New York City, and the College of Medicine has been a beneficiary of the family’s extraordinary generosity for over 35 years.

Jack Rudin is chairman of the Rudin Management Company, a major New York real estate firm. As chairman of the Louis and Rachel Rudin Foundation and the May and Samuel Rudin Family Foundation, Mr. Rudin continues the family tradition of far-sighted philanthropy begun by his grandparents, Louis and Rachel Rudin, and enhanced by his parents, Samuel and May Rudin. He has been the driving force in securing the support of the foundations for scholarships and programs at both Einstein and Yeshiva University.

“My family has an ongoing commitment to educational excellence and opportunity, qualities embodied at Einstein,” says Mr. Rudin. “Through our philanthropy, we express our resolve to continue investing in the health and greatness of our city.”
**SCIENTISTS OF THE FUTURE**

Biomedicine is where basic science and medicine intersect, making biomedical researchers crucial to translational medicine — the burgeoning field in which laboratory findings are quickly translated into drugs and other therapies to benefit patients.

The Einstein Graduate Program in the Biomedical Sciences is one of the largest and most prestigious in the country. Each year, the College of Medicine graduates 50 to 55 Ph.D. students and 10 to 12 M.D./Ph.D. students. To appreciate Einstein's commitment to educating and nurturing biomedical students as they develop into future scientists, consider the fact that the students’ tuition is paid for, and they also receive yearly stipends of $28,000.

Some aid for Einstein’s biomedical students comes from the National Institutes of Health and other organizations. But most of it comes from Einstein itself — the reason that support from donors such as the Rudin family is so important. Since the creation of the Louis and Rachel Rudin Foundation in 1973 and the May and Samuel Rudin Family Foundation M.D., Ph.D. Scholarship Fund in 1982, the Rudin foundations have provided financial aid for nearly 900 deserving students at Einstein, including three M.D./Ph.D. students each year.

Einstein’s M.D./Ph.D. program (also known as the Medical Scientist Training Program, or MSTP) trains academic medicine’s future leaders. Continually funded by the NIH since 1964, the Einstein MSTP is one of the nation’s oldest and largest: 129 M.D./Ph.D. students are enrolled, and 80 percent of the program’s 311 physician-scientist graduates work in biomedical research and academic medicine. The Einstein MSTP takes about eight years to complete and is directed by Myles Akabas, M.D., Ph.D.

Ph.D. students have received graduate education at the College of Medicine for more than 50 years. The 360 candidates enrolled in Einstein’s five-year Ph.D. program come from 28 states and 21 countries. These exceptional students are trained to become the next generation of scientific researchers.

“Our Ph.D. and M.D./Ph.D. students are the engines that drive the research in our laboratories,” says Victoria H. Freedman, Ph.D., director of the graduate programs at the College of Medicine. “They provide the hands that do the work. And their interest and curiosity not only propel things intellectually but are also vital for invigorating the faculty and stimulating the collaborative scientific spirit at Einstein.”
Einstein Alumni: Making a Difference for Future Generations of Einstein Students

Whether in clinical practice, research, global health, or academic medicine, Einstein alumni represent a remarkably broad range of professional expertise and typically go on to become leaders in their chosen fields. Their unique educational experience at Einstein inspires many of our graduates to give back to the College of Medicine. Their gifts help ensure that the next generation of Einstein-trained physicians and physician-scientists will have the same opportunities for personal and professional growth that shaped their own lives and careers.

Meet four alumni whose commitment to the College of Medicine made a difference this past year:

Herbert L. Kee
I decided to become a physician when I was 36 years old. I had a background in metallurgical engineering, but decided I wanted to work with people, not things. I was inspired after reading about Dr. Larry Mellon, who was influenced by Dr. Albert Schweitzer. So I went to visit Larry at the hospital he built in Haiti and dedicated to Dr. Schweitzer. Having started his medical career at age 39, he understood my situation and encouraged me. I had never been to a Third World country before, and the ten days I spent with Dr. Mellon reaffirmed my desire to go into medicine. My Einstein years helped refine my focus even further and brought me back to my roots to work with Chinese families on the Lower East Side.

By studying outside the U.S., in one of the many global studies programs offered at Einstein, you become aware of the cultural and physical differences of diverse populations. It opens your eyes and helps you be a better physician when you return.

My strong belief in the value of these kinds of experiences for students who are training to become physicians prompted me to support global health studies at Einstein.

Herbert L. Kee, M.D. ’70
Specialty: internal medicine, retired
Volunteer Physician at the Charles B. Wang Community Health Center, New York, NY; Dean’s Club Member

Jay M. Feingold
I spent the better part of 14 years at Einstein and loved every minute of it! I started doing basic research at the College of Medicine when I was 16, and graduated with my M.D. and Ph.D. degrees at 30. I received a complete, well-rounded education.

As a graduate student I worked in the laboratory of one of Einstein’s senior and most respected scientists. The environment was academically stimulating, friendly, and collaborative. I tried to carry this into my own academic career by creating a similar atmosphere in my own lab.

I have always found myself trying to apply “the Einstein way” to every place I have been. Now, as the head of oncology clinical research & development for a large pharmaceutical company, I am responsible for phase I-III development with team members located all over the world. Einstein prepared me for this leadership role.

My wife and I are always talking about the wonderful years we both spent in the Einstein community — a time we both hold close to our hearts. I want to make sure that Einstein students today, and in the future, have the same opportunities and come away with the same positive feelings.

Jay M. Feingold, M.D., Ph.D. ’86
Specialty: hematology
Assistant Vice President and Multi-Therapeutic Area Head, Global Medical Affairs, Wyeth Research, Wyeth Pharmaceuticals, Collegeville, PA; Dean’s Club Member
Benjamin D. Schwartz

I was recruited for Einstein’s second M.D./Ph.D. class. At that time, there were only three programs like it in the country. The mentoring, both in the clinic and at the bench, was outstanding. The professors were true giants in their respective fields and cared deeply about their students.

After earning my Ph.D. in immunology and my M.D., I spent two years as a research associate at the National Institute of Allergy and Infectious Diseases at the NIH and later was senior director of clinical research at G. D. Searle Research and Development, directing clinical trials on Celebrex®. In 1999, I co-founded the Camden Group, a consulting firm that assists biotech and pharmaceutical companies in designing clinical trials and clinical research programs.

Collaboration is key to scientific and clinical advances. I learned that at Einstein. At Camden, we work in partnership with clients and clinical and research scientists, whether it’s through designing the clinical trials to support bringing a new drug application to the FDA or by working on new applications for new formulations of existing drugs or for generic drugs.

My wife, Susan Cullen-Schwartz, M.D. ’72, Ph.D. ’71, and I contribute to Einstein to help continue the type of quality education we received and to help maintain Einstein’s reputation as a top-tier teaching and research institution. I’m glad I am able to contribute and I encourage others to support the institution that gave us so much.

Kathryn A. Crowley

Einstein has always had an open heart. It was accepting women and minorities before that was “de rigueur.”

During medical school, I had the deaths of my two parents to cope with, and the administration was very supportive. My mother was cared for by a physician at Einstein (now Einstein/Weiler) Hospital, who was wonderful to our family.

When I was a student, pediatrics was very strong at Einstein. I was taught by some of the founders in the field, and that exposure influenced my choice of specialty. The wealth of experience I received at the school’s affiliate hospitals in the Bronx was excellent. My daughter, Caitlin McMullen, now in her third year at the College of Medicine, is interested in becoming an ENT. She loves being a student at Einstein as much as I did.

I’m very grateful for my Einstein education and feel that the school needs to be supported in its endeavors to provide the best research and educational opportunities for its students. I’ll continue to give back as much as I can.
Our Supporters

**Benefactors**

Donors who have made cumulative contributions of $1 million or more toward the growth and development of the Albert Einstein College of Medicine are gratefully acknowledged as Benefactors of the College. Their names are linked forever with the proud history of the College of Medicine and its medical education and research programs.

Our new Benefactors are in boldface type on the list below:

Ebrahim Ben Davood Eliahu Eshaghian
Anne and Isidore Falk
Rose C. Falkenstein
Abraham and Lillian Feinberg
Betty and Sheldon Feinberg
Gwen and Lester Fisher
Martin A. and Emily L. Fisher
Leo and Florence Forchheimer
Leo and Julia Forchheimer Foundation
The Ford Foundation
George and Elizabeth Frankel
Estate of Charles Friedberg
Max L. and Sadie Friedman
Rachel and Samuel H. Golding
Samuel H. Golding – Jerrold R. Golding
Horace W. Goldsmith
The Horace W. Goldsmith Foundation
The Abraham and Mildred Goldstein Charitable Trust
Roslyn and Leslie Goldstein
D. S. and R. H. Gottesman Foundation
David S. and Ruth L. Gottesman
Shirley and Milton Gralla
Jeanne Gray
Raymond and Bettie Haas
Marilyn C. and Jerry S. Handler
Estate of Irma T. Hirschl
Carl C. Icahn
Joan and Ernest Kalman
Rae and Henry Kalman
Ida and Louis Katz
Marilyn and Stanley M. Katz
Mildred and Bernard H. Kayden
W. M. Keck Foundation
The Joseph P. Kennedy, Jr. Foundation
Lucille and Edward A. Kimmel
F. M. Kirby Foundation
Lola and Saul Kramer
Tamara and Charles A. Krasne
The Joan B. Kroc Foundation
Emily Fisher Landau
Mildred and William S. Lasdon

**Ethel and Samuel J. LeFrak**

Estate of Bertram Leslie
in memory of Nathan and Julia Levy
The Levitt Foundation
Benjamin J. and Anna E. M. Levy
Jacob P. and Estelle Lieberman
The Gruss Lipper Family Foundation
Marcia and Ronald Lissak
Frances and Herman Lopata
Evelynne and Max M. Low
Evelyn and Joseph I. Lubin
H. Bert and Ruth Mack
Lucille P. Markey Charitable Trust

**Estate of Marie Markus**

The G. Harold and Leila Y. Mathers Charitable Foundation
Ruth Mens
Sydelle and Arthur I. Meyer
Diane and Ira M. Millstein
Marco and Louise Mitrani
Selma and Dr. Jacques Mitrani
Sammy and Aviva Ofer
Sylvia and Robert S. Olnick
Sidney and Miriam Olson
Arnold S. Penner and Madaline Berley
Pew Charitable Trust
Laura and John J. Pomerantz
The Price Family Foundation
Terry and Asriel Rackow
Estates of Benjamin, Minna, and Robert A. Reeves
Ingeborg and Ira Leon Rennert
Jack and Pearl Resnick
Judith and Burton P. Resnick
Charles H. Revson
Ingeborg and Ira Leon Rennert
Jack and Pearl Resnick
Charles H. Revson
Rita and Philip Rosen
Judy R. and Alfred A. Rosenberg
Hedwig and Ernst Roth
Julia and Eli L. Roussou
Louis E. and Dora Rousso
Florence and Irving Rubinstein

**Estate of Lila Rudin**

The Rudin Family
Bernice L. and Cecil Rudnick
The Family of Chella and Moise Safra
Edmond J. Safra/Republic National Bank of New York
Anita and Jack Saltz
Sol T. and Hortense Scheinman
Helen and Irving Schneider
David and Irene Schwartz
The Beatrice and Samuel A. Seaver Foundation
Dorothy and Marty Silverman
Nina Silverman
Patty and Lorin Silverman
Sydel and Michael Singer
Branna and Irving Sisenwein
The Skirball Foundation
Estate of Sidney Solid
The Helen and Irving Spatz Foundation
Benjamin and Frances Sperling
Estate of Helen Stein
Jeffrey J. Steiner
Estate of Margarethe I. Stern
Louise and Michael Stocker
Leo and Rachel Sussman
Siegfried and Irma Ullmann
Jack D. and Doris Weiler
Evelyne and Murray Weinstein
Jacob D. and Bronka Weintraub
Edna and K. B. Weissman
Zygmunt and Audrey Wilf

**Benjamin and Susan Winter**

Eliot K. and Nancy Wolk
The Wollowick Family Foundation
**Honor Roll**

Albert Einstein College of Medicine gratefully acknowledges all contributions to its medical education and research programs from alumni, families, individuals, corporations, foundations, trusts, and estates. The following list recognizes cash gifts received during the fiscal year ended June 30, 2008, and includes payments toward pledges made in prior years.

*Black type reflects an Einstein alumnus or alumna*

† Deceased

### $1,000,000 and above

- FJC - A Foundation of Philanthropic Funds
- David S. and Ruth L. Gottesman
- Marilyn and Stanley M. Katz
- Ethel and Samuel J. LeFrak
- The Gruss Lipper Family Foundation

- The Price Family Foundation
- Ingeborg and Ira Leon Rennert

### $500,000 to $999,999

- Doris Duke Charitable Foundation
- Roslyn and Leslie Goldstein
- Beatrice and Samuel A. Seaver Foundation
- Anonymous

### $250,000 to $499,999

- Alpern Family Foundation
- Altira Group, Inc.
- The Breast Cancer Research Foundation, Inc.
- Horace W. Goldsmith Foundation
- The High Q Foundation, Inc.
- F. M. Kirby Foundation
- G. Harold and Leila Y. Mathers Charitable Foundation
- The James S. McDonnell Foundation
- Judith and Burton P. Resnick Foundation
- Louis and Rachel Rudin Foundation, Inc.
- Chella and Moise Safra Foundation
- Branna and Irving Sisenwein The Skirball Foundation
- Samuel Waxman Cancer Research Foundation
- Zygmunt and Audrey Wilf Foundation

### $100,000 to $249,999

- Linda and Earle Altman
- American Federation for Aging Research
- Autism Speaks
- Judy and Ron Baron
- Robert M. Beren, for the Robert M. Beren Foundation, Inc. and Israel Henry Beren Charitable Trust, Robert M. Beren, Trustee
- Janet Burros Memorial Foundation
- Burroughs Wellcome Fund
- Damon Runyon Cancer Research Foundation
- Susan and Kevin Davis
- Ellison Medical Foundation
- Entertainment Industry Foundation
- Jeffrey P. Feinman
- FRAXA - Fragile X Research Foundation
- Manny and Myra Genn
- Glenn Foundation for Medical Research
- Iranian American Jewish Federation of New York
- Jesselton Family
- Robert Wood Johnson Foundation
- Tamara and Charles A. Krasne
- Betty and Norman F. Levy Foundation
- Charles H. Revson Foundation
- The Robin Hood Foundation
- Daniel E. Rothenberg
- The Rosanne H. Silbermann Foundation, Inc.
- The Alexandrine and Alexander Sinzheimer Foundation
- The Helen and Irving Spatz Foundation
- Sheryl and Daniel R. Tishman
- The Wollowick Family Foundation

### $50,000 to $99,999

- Renée E. and Robert A. Belfer Chemotherapy Foundation, Inc.
- Roula and Neil A. Clark Dana Foundation
- Dana’s Angels Research Trust
- Emerald Foundation, Inc.
- Betty Feinberg Joa’s Legacy: Uniting Against Lung Cancer
- Lymphoma Research Foundation
- The Mesothelioma Applied Research Foundation, Inc.
- Diane and Ira M. Millstein
- Suzanne and Thomas S. Murphy
- NARSAD
- New York Community Trust
- New York Stem Cell Foundation, Inc.
- Ara Parseghian Medical Research Foundation
- Steven E. Pegalis
- Arnold S. Penner and Madalene Berley
- Dr. Seymour L. Romney
- Rita and Philip Rosen
- Doris and Myron Saranga
- Alfred P. Sloan Foundation
- Susan G. Komen for the Cure United Negro College Fund, Inc.
- Kathy and Samuel G. Weinberg
- Elliot K. and Nancy Wolk Foundation

### $25,000 to $49,999

- The American Society of Hematology
- Elaine and Alan Ascher Atran Foundation
- Austin Family Fund
- Children’s Tumor Foundation

### Dr. Keith D. Chirgwin

- Francis Family Foundation
- Fund for Social Change
- Lori and Adam S. Gottbetter
- The Greenberg Breast Cancer Research Foundation, Inc.
- Janet and Arthur N. Hershart
- Beatrice Hollander
- Selma Hollander
- Harry and Rose Jacobs Foundation, Inc.
- Dr. Steven G. Kaali
- Joan and Ernest Kalman
- Fritz and Adele Kaufmann Foundation

### Dr. Herbert L. Kee

- The Edward and Lucille Kimmel Foundation
- Penny M. and David J. Klein
- Judy and Paul J. Konigsberg
- Lauri Strauss Leukemia Foundation
- James P. Levin
- Ruth and David Levine Helen and Rita Lurie Foundation
- Phyllis and William L. Mack Arlene and Mitchel A. Maimon Gertris F. Marx Foundation Sylvia Marx
- National Kidney Foundation

### National Lung Cancer Partnership

- National Niemann-Pick Disease Foundation, Inc.
- Byron Nimocks
- Mr. and Mrs. Robert C. Pearl
- Jack and Pearl Resnick Foundation
- Jack and Anita Saltz Foundation, Inc.
- Jane and Larry B. Scheinfeld
- Ruth and Irwin Shapiro
- Louise and Michael Stocker
- Stony Wold-Herbert Fund, Inc.
- Janice and Sol Tanne
- THANC Foundation, Inc.
- Diane and Thomas E. Tuft
- Miriam and Ira D. Wallach Foundation
- Sylvia Weissman
- The Helen Hay Whitney Foundation

### $10,000 to $24,999

- Richard Abrams
- Ruth and Dr. Louis M. Aledort
- Joseph Alexander Foundation, Inc.
- The Norman E. Alexander Foundation
- Barbara and Philip Altheim
- American Health Assistance Foundation
- The Balm Foundation
- Caryn Becker
- Marjorie Diener Blenden
- Ruth and Louis Brause
- Marion Brechner
- Sara Chait Memorial Foundation, Inc.
- Steven Chestler
- Ann E. Cohen
- Raymond S. Cohen
- Suzanne M. and Edward Baron Cohen
- Ann and Sam Colin
- Helen J. DeVos
- Roni and Stuart Doppelt
- Dr. Scholl Foundation
- Robert R. Dyson
- Carol and Roger W. Einiger
- Dr. Scholl Foundation
- Steven Dyson
- Carol and Roger W. Einiger
- Simone and David Eshaghian
- Arlene Farkas and H. Kenneth Sidel
- Farrell Building Company, Inc.
- Michael Feigin
- Bambi and Roger Felberbaum
- Fidelity National Title Insurance Co. of New York
- Joyce and Jeffrey Fiedler
- Peter Fine
Our Supporters

Linda and Gregory E. Fischbach
Fisher Scientific
International, Inc.

Dr. Ruth Freeman and
Robert Lewis
GKK Capital Corp.
George J. Gillespie III
Gloria and Herbert Glatt
Mary and Jay N. Goldberg
Barbara Goldsmith
Emily and Eugene M. Grant

Dr. Stephanie A. and
Stephen J. Green
Stephen Green
Michael K. Greenside
Bernard Groveman
Marcia Hill and Guy Miller
Struve
Morton P. Hyman
Anne and Robert J. Ivanhoe
Richard S. Jaffé
Tinku and Dr. Ajit Jain
Sandra and Nathan S. Kahn
Erica and Michael Karsch
Amy and Neil S. Katz
Frederick Klingenstein
Emily Fisher Landau and
Sheldon Landau
Nancy and Jeffrey Lane
Bonnie Englebardt Lautenberg
Dr. Herbert J. Levin
Bonnie Englebardt Lautenberg
Dr. Emanuel T.
Richard A. Pearl
Nash Family Foundation

Migraine Research
Foundation, Inc.

Dr. Magdy Mikhail
Cheryl and Michael Minikes
Nash Family Foundation
Richard A. Pearl

Iris G. and Dr. Emanuel T.
Phillips
Prevent Cancer Foundation
RBC Dain Rauscher
Foundation

George Roach
Carol and Martin* Roaman
Marian and David Rocker
Mary Ellen Rogers
Judy R. Rosenberg*

Susan and Dr. Steven P.
Rosenberg

Helen and Dr. Ronald J. Ross
Daryl and Steven Roth
Yael P. and Dr. Norman A.
Saffra
Mara Sandler
Richard A. Schechter
Harvey Schulweis

Marsha and Jerry M. Seslowe
Carl Shapiro
Renée Shapiro

Dr. Jeffrey A. Stahl
Judy and Michael Steinhardt
Foundation

Dr. Jack Stern
Carol Stone
Louis Tomson
Towers League for Einstein
Cancer Research
Karel Fierman Wahrsager
Rebecca Cooper Waldman
Mary J. Wallach
The Weisman Family
Foundation
Isidor Wiesbader
Foundation, Inc.
Irene Winkelman
Helene Wolcho
Lois and Martin Zelman

$5,000 to $9,999
Hope and Marc Altheim
Debra and Glenn R. August
Robin Dubin Avram
Christina and Robert C. Baker
Helaine M. and Victor J. Barnett
Dr. Jayne G. and Harvey Beker
Diane Belfer
Linda and Peter Berley
Blank Rome, L.L.P.

Dr. Morton D. Borg
Lotte and Ludwig Bravmann
Joanne Bross
Lois Brounell
Daniel B. Burke
Rosemarie Caiola
Dr. Cynthia Chazotte
Drs. Esther and Ben Chouake

Dr. Kathryn A. Crowley
Marvin H. Davidson
Glenn Davis
Dr. Nancy E. DeVore
Diabetes Action Research and
Education Foundation
Douglas Donaldson
Rose Dreyer
Donald Dwares
Judy Elbaum
Drs. Rene Elkin and Gary L.
Goldberg
Marjorie and Robert B. Emden
Mindy and Marc A. Feinberg
Amy Feinblatt
Caryl and Dr. Jay Marshall
Feingold
Cary Fields
The Finkenstein Foundation, Inc.
Pamela Fiori
Gwen and Lester Fisher

Lynn and Dr. Allen J. Fishman
Paula and David S. Fishman
Richard J. Fleder
Joseph F. and Clara Ford
Foundation
Edward L. Gardner
Bonnie and Peter Gatof
Hermine Gewirtz
Debbie and Elliot Gibber
Edythe and Matthew L.
Gladestein
Allan H. Glick
Sarah B. and Seth Glickenhaus
Terri and Michael W. Goldberg
Greg Gonzales
Barbara Fried Gottesman
Bonnie Gregge
Mr. and Mrs. Martin D. Gruss
Mr. and Mrs. Joseph Gurwin
Orly Hackman
Marilyn C. and Jerry S. Handler
David Himelberg Foundation
Gerry H. Hodes
Betty G. Hut
Deanne* and Arthur I. Indursky
Mrs. A. Jane Jaffe
Robert M. Jaffe
Barbara and Donald Jonas
Elliot Kamen
Renne T. and Daniel R. Kaplan
Karen and Stephen R. Karafiol

Dr. Monique C. and Mordecai
D. Katz
Susan and Mel Katz
Alice and Ira Kent
Ruth and David Kestenbaum
Shelly and Dr. Howard N.
Kivell
Doris and Dr. Ira Kukin
Shawn Leibowitz
Anne Claire Lester
Foundation, Inc.

Dr. Miriam Levy
Karen and David Mandelbaum
Jeffrey Mann
Dr. Leon Mann
Jeffrey Maron
Isidore Mayrock
Gus Mazza

Drs. Michelle and
David M. Merer
Ethel Meyer
Diene Miller
Jim Millstein
Vanita and Raju Mirchandani
Lester Morse
Alfred H. Moses

Sue and Dr. Noel Nathanson
Steve Nelson
Northville Industries Corp.
Samuel G. Oberlander, M.D.
Foundation

Jane C. and Daniel S. Och
Nancy and Morris W. Offit
Old Oaks Foundation, Inc.
Our Lady of Mercy Medical
Center
Dean Palin
Joan R. Picket
John G. Pieper

Barbara E. Pollard and
Dr. Mitchell B. Stein
Laura and John J. Pomerantz
Paula and Ira M. Resnick
Nataly and Toby G. Ritter
Roseman Foundation
Daniel Rosenbloom
Pat and John Rosenwald
Eric A. Rothfeld
Norman and Constance Sadek
Foundation
Alexander Samilenko
Dr. Nanette Santoro
Lisa Schenker
Walter J. Schloss
Charlotte Schoenfeld
Lori and David H. Schwartz
Margaret Sedis and
Dr. Matthew Goldstein
Marvin and Hazel Shanken
Tracy and Stanley Shopkorn
Adrienne and William Silver
Ellen and Morton F. Silver
Jo Ann and Dr. Samuel C.
Silverstein

Drs. Gail E. Solomon and
Harvey L. Hecht
Anne and Bernard Spitzer
Andrea Stark
Sterling National Bank
Ellen L. and Jerome L. Stern
David Tanner
Judy Tenney
Jonathan Tisch
Wilma S. Tisch

Drs. Pilar Vargas and
Sten H. Vermund
Sue and Edgar Wachenheim III
Foundation

Dr. Paul I. Wachter
Stephanie and Harry Wagner
Sandra and Marvin D. Wax
Sue Ann Weinberg
Dr. Joyce Gútor Wolf
Richard M. Wyman
Anonymous

$1,000 to $4,999
Dr. Marcelle L. Abell-Rosen
Benjamin W. Abrams
Daniel Ian Abrams
Dr. Emanuel M. Abrams
Science at the heart of medicine

Larissa and Joshua M. Abrams
Jordana Abrams-Snider and Scott Snider
Accounteks, L.L.C.
Julie Ader
Jane Ades
Catherine George and Frederick R. Adler
Dr. Daniel G. Adler
AFD Contract Furniture
Dr. Stewart L. Aledort
Faisal Almahdi
Claire Alpert
Stephens N. Bobrow
Karen and Dr. Rex Bolin
Stacey and Michael Bonagura
Rita and Dr. Lawrence I. Bonchek
Jane K. Boorstein
Drs. Lisa B. and Bradford S. Bootstaylor
Douglas Borck
Marian and Richard Bott
Enid Boxer
Leonard Boxer
Gabriel Leigh Boyar
Joel Boyarsky
Gerry Boyle
Drs. Ira F. Braun and Lyn Nadel
Dr. John M. Braver
Louise Braver
Robert A. Breakstone
Sandra Breakstone
Dr. Jeffrey A. Breall
Michelle Breitschneider
Alison Brod
Bert Brodsky
Dr. Julia Brody
Matthew Bronfman
Robertta and Richard D. Brudner
Carole and Dan Burack
Dr. Carol Burg
Chaya and Dr. Edward R. Burns
Marlon Bustos
Todd Buson
Millicent Calicchio
Louise and Vincent Camuto
David L. Cannold
David A. Cantor
Michael Capasso
Gene Cardoza
Gillian Salama Caro
Emily Carrera
Linda and Arthur L. Carter
Vera and Philip L. Chapman
Elisa and Brian Charters
Martin Chelnick
Judith Chervenak
Dr. Edward Chock
Melinda Chu
Shirley and Dr. Howard Chung
Dr. Sarah Church
Judith and Dr. Joseph M. Clark
Eric Clementi
Virginia and James Clerk
Margie L. Cohen-Barres
Andrew B. Cohen
Bryn Roberts Cohen
Carol Feinberg Cohen
Elias A. Cohen Foundation, Inc.
Drs. Marjorie and Mark Cohen
Maya Cohen
Barbara B. and Bertram Cohn
Hugh Corben
Jeffrey Corbin
Corinthian Realty Partners, L.L.C.
Sheila Cornstein
Dana Cowin
James W. Crystal
Drs. Susan Cullen-Schwartz
and Benjamin D. Schwartz
Christine W. Curtis
Drs. Susan and Brian J. Cusin
Michael Dalewitz
Rachel and Mark Dalton
Dr. Ethelyn D. Daniel
Gari Hill and Ira M. Dansky
Drs. Faranak Daravi
and Farshad J. Nosratian
Betty and Robert David
Nina Davidson
Dr. Jay M. Davis
Barbara De Portago
Mark DeFazio
Joseph Deglomini
Stephen J. Degroat
Charles J. De Priore, Jr.
Helen and Philip Delman
Foundation, Inc.
Dematteo Monness, L.L.C.
Edward DeRocco
Adam Deutsch
Beth Rudin DeWoody
Leslie Dezer and Ricardo A. Salmon
Ruby Diamond Foundation
Jeremy W. Dickens
Deborah R. and Dr. Douglas A. Drossman
James P. Druckman
Marcia Dunn
Shelly and Dr. Peter Dunn
Patricia J. and Dr. Edward M. Dwyer
Edgewater Foundation, Inc.
Anne and Joel S. Ehrenkrantz
Dr. Murray N. Ehrinpreis
Ingrid Arneberg
Dr. Jacqueline Avin
Brenda Axelrod
Steven Ball
Eric Bamberger
Allison Bandier and Jeffrey Koffman
Martin Bandier
Erika Banks
Natalie Barth
Ruth Baum
Dr. Stephen G. Baum
Irving P. Baumrind
Frances and Andrew Benerofe
Drs. Ian D. and Anne Benham
Stacey L. and Michael A. Bennett
Dr. Judith Benstein
Allison Berg
Martin S. Berger
Max W. Berger
William H. Berkman
Howard Berkowitz
David I. Berley
Robert A. Bernhard
Norma and Dr. Irwin B. Bernhardt
Pamela Bernstein
Scott Bernstein
Michele Beyer
Ann and Kenneth J. Bialkin
Dr. Alan J. Bier
Caryn Bilzin
Drs. Leslie and Paul S. Blachman
Dr. Christine E. Blackwell and
Kenneth de Got
Dr. Andrew Lewis Blank
Richard D. Blaser
Dr. Mark H. Blecher
Barbara H. and James A. Block
Dr. Glenn T. Bloiso
Abbey Blum
Charlotte and Roger A.
Blumencranz
Susan and Edward R.
Blumenfeld
Stephen N. Bobrow
Karen and Dr. Rex Bolin
Stacey and Michael Bonagura
Rita and Dr. Lawrence I. Bonchek
Jane K. Boorstein
Drs. Lisa B. and Bradford S. Bootstaylor
Douglas Borck
Marian and Richard Bott
Enid Boxer
Leonard Boxer
Gabriel Leigh Boyar
Joel Boyarsky
Gerry Boyle
Drs. Ira F. Braun and Lyn Nadel
Dr. John M. Braver
Louise Braver
Robert A. Breakstone
Sandra Breakstone
Dr. Jeffrey A. Breall
Michelle Breitschneider
Alison Brod
Bert Brodsky
Dr. Julia Brody
Matthew Bronfman
Robertta and Richard D. Brudner
Carole and Dan Burack
Dr. Carol Burg
Chaya and Dr. Edward R. Burns
Marlon Bustos
Todd Buson
Millicent Calicchio
Louise and Vincent Camuto
David L. Cannold
David A. Cantor
Michael Capasso
Gene Cardoza
Gillian Salama Caro
Emily Carrera
Linda and Arthur L. Carter
Vera and Philip L. Chapman
Elisa and Brian Charters
Martin Chelnick
Judith Chervenak
Dr. Edward Chock
Melinda Chu
Shirley and Dr. Howard Chung
Dr. Sarah Church
Judith and Dr. Joseph M. Clark
Eric Clementi
Virginia and James Clerk
Margie L. Cohen-Barres
Andrew B. Cohen
Bryn Roberts Cohen
Carol Feinberg Cohen
Elias A. Cohen Foundation, Inc.
Drs. Marjorie and Mark Cohen
Maya Cohen
Barbara B. and Bertram Cohn
Hugh Corben
Jeffrey Corbin
Corinthian Realty Partners, L.L.C.
Sheila Cornstein
Dana Cowin
James W. Crystal
Drs. Susan Cullen-Schwartz
and Benjamin D. Schwartz
Christine W. Curtis
Drs. Susan and Brian J. Cusin
Michael Dalewitz
Rachel and Mark Dalton
Dr. Ethelyn D. Daniel
Gari Hill and Ira M. Dansky
Drs. Faranak Daravi
and Farshad J. Nosratian
Betty and Robert David
Nina Davidson
Dr. Jay M. Davis
Barbara De Portago
Mark DeFazio
Joseph Deglomini
Stephen J. Degroat
Charles J. De Priore, Jr.
Helen and Philip Delman
Foundation, Inc.
Dematteo Monness, L.L.C.
Edward DeRocco
Adam Deutsch
Beth Rudin DeWoody
Leslie Dezer and Ricardo A. Salmon
Ruby Diamond Foundation
Jeremy W. Dickens
Deborah R. and Dr. Douglas A. Drossman
James P. Druckman
Marcia Dunn
Shelly and Dr. Peter Dunn
Patricia J. and Dr. Edward M. Dwyer
Edgewater Foundation, Inc.
Anne and Joel S. Ehrenkrantz
Dr. Murray N. Ehrinpreis
Ingrid Arneberg
Dr. Jacqueline Avin
Brenda Axelrod
Steven Ball
Eric Bamberger
Allison Bandier and Jeffrey Koffman
Martin Bandier
Erika Banks
Natalie Barth
Ruth Baum
Dr. Stephen G. Baum
Irving P. Baumrind
Frances and Andrew Benerofe
Drs. Ian D. and Anne Benham
Stacey L. and Michael A. Bennett
Dr. Judith Benstein
Allison Berg
Martin S. Berger
Max W. Berger
William H. Berkman
Howard Berkowitz
David I. Berley
Robert A. Bernhard
Norma and Dr. Irwin B. Bernhardt
Pamela Bernstein
Scott Bernstein
Michele Beyer
Ann and Kenneth J. Bialkin
Dr. Alan J. Bier
Caryn Bilzin
Drs. Leslie and Paul S. Blachman
Dr. Christine E. Blackwell and
Kenneth de Got
Dr. Andrew Lewis Blank
Richard D. Blaser
Dr. Mark H. Blecher
Barbara H. and James A. Block
Dr. Glenn T. Bloiso
Abbey Blum
Charlotte and Roger A.
Blumencranz
Susan and Edward R.
Blumenfeld
Stephen N. Bobrow
Karen and Dr. Rex Bolin
Stacey and Michael Bonagura
Rita and Dr. Lawrence I. Bonchek
Jane K. Boorstein
Drs. Lisa B. and Bradford S. Bootstaylor
Douglas Borck
Marian and Richard Bott
Enid Boxer
Leonard Boxer
Gabriel Leigh Boyar
Joel Boyarsky
Gerry Boyle
Drs. Ira F. Braun and Lyn Nadel
Dr. John M. Braver
Louise Braver
Robert A. Breakstone
Sandra Breakstone
Dr. Jeffrey A. Breall
Michelle Breitschneider
Alison Brod
Bert Brodsky
Dr. Julia Brody
Matthew Bronfman
Robertta and Richard D. Brudner
Carole and Dan Burack
Dr. Carol Burg
Chaya and Dr. Edward R. Burns
Marlon Bustos
Todd Buson
Millicent Calicchio
Louise and Vincent Camuto
David L. Cannold
David A. Cantor
Michael Capasso
Gene Cardoza
Gillian Salama Caro
Emily Carrera
Linda and Arthur L. Carter
Vera and Philip L. Chapman
Elisa and Brian Charters
Martin Chelnick
Judith Chervenak
Dr. Edward Chock
Melinda Chu
Shirley and Dr. Howard Chung
Dr. Sarah Church
Judith and Dr. Joseph M. Clark
Eric Clementi
Virginia and James Clerk
Margie L. Cohen-Barres
Andrew B. Cohen
Bryn Roberts Cohen
Carol Feinberg Cohen
Elias A. Cohen Foundation, Inc.
53
Science at the heart of medicine
Our Supporters

Dr. Andrew A. Stolz
Paula and Michael Stoler
Dr. Penny M. Stern
Elizabeth and Walter P. Stern
Bonnie B. and Steven E. Stern
Stephen Sules Agency, Inc.
Renee Steinberg
Tara Stein
Matthew Stein
Louise and Michael Stein
S. Tisch
Dr. Andrew A. Toolin
Jean and Raymond Troubh
Nancy Tsai
Suzanne Turkewitz
Terry Underberg
United Capital Corp.
Nathaniel H. Usdan
Josephine and Gennaro
Volgende Charitable Trust
W D F, Inc.
Allison Wallach
Kenneth L. Wallach
Penny Wallerstein
Donald E. Walsh
Dr. Jy-Ming Wang and Charles
Zuniga
Anne Warner and Michael A.
Makuch
Deborah P. Warner and
Michael N. Ungar
Nancy and Dr. Jonathan R.
Warner
Robert Warner
Vivian Wassaf and Dr. Maguid
Ramzi Megalli
Ellen and Dr. Richard B. Weber
Jane E. and Craig J. Wehrli
Penny and Jeffrey L. Weill
Marshall Weinberg
Barbara J. and Dr. Mark
Weinblatt
Ronald G. Weiner
Dr. Barbara S. and Alan
Weinschel
Drs. Elin Shari Weinstein and
Abraham R. Freilich
Leonard M. Weintraub
Robert M. Weintraub
Carol Weiser
Carol Weisman
Judy and Morry J. Weiss
Julie Weiss
Stanley Weiss
Adrienne Weissman
Howard Wendy
Barbara K. and Dr. Stephen A.
Werrheimer
Bruce Wiener
Carolyn Wiener
WiF Family
Dr. David Witosky
Drs. Lisa and Burton J.
Witosky
Joan W. and William Witkin
Elinor Wohl Cohen
Lester Wohl
Marlean and Dr. Kenneth J.
Wolf
Patricia and Russell E. Wolff
Sylvia and William Wolff
Laurie Wolk
Gerald Wolkoff
Dr. Donald H. Wolmer
World Communications, Inc.
Suzanne Yadav
Julie N. and Mark E. Yadgaroff
Dr. Z. Asher Yama
Peter Yu
William D. Zabel
Dr. Lisa R. Zablocki
Michael Zacharias
Cynthia Zeger
Lois and Bruce Zenkel
Laura Zeppieri
Dr. Arthur Zimmerman
Ellen F. and Dr. Robert
Zimmerman
Jane Zimmerman
Peter Zimmam
Mr. and Mrs. Seymour W. Zises
Christina Zunker
Anonymous

$500 to $999

Rocco Abbate
Carol Abrams
Debbie Abrams
Robert E. Abrams
Vicki S. and William H.
Abrams
Jay B. Abramson
Leslie J. Adler
Drs. Ingrid and Stewart Albert
Susan Albright
Michael H. Alderman
Kent B. and Dr. Diane Z.
Alexander
Wendy Alper
Debra and Daniel Alpert
Rachel and Julius? Angstrech
Merrie A. and Dr. Eli Anker
Sara and Dr. Benjamin Z.
Arbesfeld
Karen J. and Dr. Ira H. Asher
Sylvia Atkins
Walter Austerer
Robin Aviv
Maria and Dr. Morrell Michael
Avram
Susan K. Baker
Dr. Denes V. Balazs
Liza Ball
Harriet Ballon
Staci B. Barber
Corey Barkoff
Lisa Gerevitz Barr
Donna C. and Dr. Earl Barron
Martin J. Barschi
Audrey Bartner
Missy Basile
Elisabeth A. Bassin
Arleene F. Bearak
Tracy Becker
Michael Beerman
Claudia and Kevin Bell
Susan J. Bender
Judith Berk
Alan M. Berly
Laurie Berman
Phyllis and Martin Berman
Randi Berman
Arlene Bernstein
Julie Bernstein
Dr. Robert G. Bernstein
Drs. Stephanie Bernstein and
Franklin D. Segall
Ruth A. and Dr. Chester M.
Berschling
Elaine and Arthur H.
Bienenstock
Dr. Lawrence Blacher
David Blechman
Kathy Bleznak
Miriam and Dr. Jeffrey Block
Lisa Bochner
Roberta Bogen
Lisa Borodkin
Barbara Bosses
Judi and Dr. Jay L. Bosworth
William B. Bram
Our Supporters

Amy Kanef
Jeanne Kann
Dr. Lawrence Kaplan
Peter M. Kaplan
Melissa and Marc Karetisky
Dr. Kris M. Karlen
Eileen Karp
Loryn Cohen Kass
Nanette Kass
Corrine Katz
Erica Katz
Dr. Jack Maynard Katz
Martin Katz
Nancy Katz
Dr. Sheldon Katz
Joan B. Kaufman
Mr. and Mrs. Joel D. Nathan
Kazis
Kyle D. Kelly
Dr. Dawnielle J. Kerner
Kery, L.L.C.
James G. King
Susan Kingsolver
Dr. Richard N. Kitsis
Carol and Allen Klein
Dr. Nora A. Klein
Dr. Richard M. Klein
Dr. Michael Kligerfeld
Dr. Deborah Kliger
Jeanne Kliger
Howard Koeppe
Faith Kates Kogan
Julia Kohane
Gloria Konigsberg
Barbara and Dennis Konner
Diane Koplik
Ann Z. Korelitz
Paul Kornfeld
Tamarah Behan Kornstein
Fay and Dr. Harvey N. Kranzler
Jesse Krasnow
Helene and Dr. Barry S.
Krauschaar
Drs. Sherry Lynne and Robert
Krausz
Dr. Richard D. Kremsdorf
Erica Linn Kronick
Krupman Family Foundation, Inc.
Dr. Joshua Kunin
Dr. Shiu Y. Kwok
Bartley R. Labinger, D.D.S.
Dr. Robert E. Lambiase
Rivkie and Dr. Joshua B. Lamm
Marlene Landau
Lorrie and Michael Landsberg
Drs. Sophie Lanzkron and
Daniel J. Salzberg
Ruth and Sidney Lapidus
Rena and Leonard Lauren
Rachel Laxer
Miriam and Herbert Lazar
Dr. Minh-Michael V. Le
Susan and Alan Leavitt
Cheryl LeFkovitz
Denise C. LeFrak and John Calicchio
Niloufar and Dr. Rudolph L.
Leibel
Ludwig Leibsohn
Stacy H. Lesser
Arlene and Arthur Levine
Edwin Levine
Dr. Ilissa Joy Levine
Simone Levinson
Carol F. and Dr. Fredric E.
Levison
Alan Levy
Arlene Levy
Martin R. Lewis Charitable
Foundation, Inc.
Dr. George P. Liakeas
Lisa Licht
Ellen M. Lieb
Theodore R. Lilley
Laurie Lindenbaum
Drs. David A. and Margaret R.
Link
Susan Lipsitz
Mimi S. Livingston
Jan G. and Dr. Jerome M. Loew
Dr. Gary Lombardi
Ilyssa Londa
Dr. Barry London
Longhill Charitable Foundation
Kristine S. and Dr. Robert S.
Lupi
Barbara P. and Dr. Paul A.
Lusman
Paula Mitran Lustbader
Linda F. Lynn
Kevin Magid
Greg Maidman
Nancy Ann Majteles
Dr. Suann L. and Stephan
Mallenbaum
Sean M. Malone
Jennifer G. Mantz
Drs. Paula Marcus and Steven
Safer
Drs. Lewis Markoff and
Caroline Samuels
Sandra and Norman Marrow
Dr. Abigail M. Martinez
Mary M. Martorri and Dr.
Mervyn R. Stein
Dr. Nathaniel Mayer
Dr. Kathleen McCabe
Carol Mehler
Dr. Mark F. Mehler
Susan Mendik
Dr. Steve Menna
Harriet Merewitz
Geraldine and Norman J.
Merkusamer
Ellen Meyers and Dr. Barry N.
Neeland
Kim and Evan Meyers
Dr. Peter B. Milburn
Elaine Miller
Marjorie Miller
Jamie and David Mitchell
Paula Modell
Robin Modell
Dr. Harriette R. and Malcolm
D. Mogul
Alfred H. Morris
Lisa Musa
Ruth Naidus
Belkis Nasser
Nelson Management Group, Ltd.
Lisa and Dr. Scott E. Nelson
Renee Nelson
Judith Ness and Dr. Seth L.
Ness
Alice Netter
Dr. Noelle B. Nielsen
Alissa Nierenberg
Lynda Nitabach
Dr. Sonya S. Noh
Carole Ohlan
Helene G. and Martin J.
Oppenheimer
Diane R. and Dr. Walter A.
Orenstein
Deborah A. Hrustich and
Dr. Paul R. Osterdahl
Jason and Tricia R. Pantzer
Lillian and Dr. Barry Paul
Tara Pearl
Andrew M. Perez
Leslie Perkins
Beverly Perry
Theresa Pisacani and Anthony
Scotto
Platinum Maintenance Services
Corp.
Marilyn and Herbert B. Platzner
Esther K. Plotner
Bernice Podell
Geri Pollack
Mona M. and Dr. Murray M.
Pollack
Louise and Dr. Alan Polsky
Joseph Pontarelli
Dr. Abraham Port
Alyssa Port
Lara Portela
Barbara Portman
Dr. James B. Post, IV
Pamela Pranzo
Premier Contracting of NY, Inc.
Jodi Press
Alix Prince
Steven J. Prince
Rodney Propp
Penny and Dr. Dominick P.
Purpura
Stacy Quarry
Joshua N. Rabbani
Nancy N. Radin-Tarnoff
Cathy L. and Dr. Neal E. Rakov
Stacy Rappaport
Nancy Shaw and Walter Raquet
Sandra H. and Dr. Arnold C.
Ratner
Alison Rauch
Arlene S. Redner-Wikes
Lynn H. and Dr. Michael J.
Reichgott
Dr. Stephanie B. Rein
Judy Reiner and Dr. Roger Platt
Drs. Dori B. and Stephan
Reissman
Arthur Remillard, Jr.
David Alan Resnick
Ina and Allen N. Rich
Michael Richman
Marion and Dr. Robert C.
Richter
Monica Richter
Alison and Dr. Ronald
Richterman
Nancy Rieger
Ben Ringel
Dr. Gary T. Robinson
Christina Rose
Robin G. and Dr. Douglas
Rosen
Rona and Dr. Michael H. Rosen
Selma and Martin W. Rosen
Dr. Alan S. Rosenberg
Evelyn B. and Dr. Gary A.
Rosenberg
Henrietta K. and Dr. Henry
Rosenberg
Miriam and Dr. Howard W.
Rosenblum
William Rosengarten
Dr. Carl E. Rosenkilde
Richard and Hinda Rosenthal
Foundation
Zita G. Rosenthal
Dr. Martin S. Roshco
Amanda Ross
Drs. Mary M. Ross and Eric G.
Dolen
Dr. Richard J. Ross
Susan Roth
Evan Roth
Meg Roth
Dr. Jonathan Alan Rothblatt
Dr. Peter Rothstein
Julia Roussu
Lenore Ruben
Eric Rudin
Science at the heart of medicine

Every effort has been made to ensure the accuracy of the information provided. We very much regret any errors or omissions that may nevertheless have occurred.

ESTATES AND TRUSTS

Gifts from the estates and trusts listed below were received during the period from July 1, 2007 to June 30, 2008. We greatly appreciate their legacy of caring and support.

Estate of Andrè Aisenstadt
Estate of David B. and Rosalind W. Alcott
Estate of Albert A. Berger
Estate of Sylvia Braun
Estate of Lillian Brody
Monique Weill Gaulier Trust
Estate of Mirrel Davis
Estate of Sylvia Davis
Estate of Robbert Davis
Estate of Lillian Davis
Estate of Jeanette Friedman
Estate of Mildred Golombek
Goodstein Memorial Trust
Estate of Manny Hilman
Estate of Pharma
Estate of Herbert J. Kanasy
Estate of Estelle Knapp
Estate of Libra Levine
Estate of Marie Markus
Margaret Sherlin Meltzer Trust
Estate of Joan Miller
Dr. Mildred Morehead
The Estate of Alexander Nadel
Estate of Saul Ritter
Estate of Lila Rudin
Estate of Eve Scheinberg
Estate of Fannie Sender
Estate of Larry Stock

PLEASE NOTE:

Every effort has been made to ensure the accuracy of the information provided. We very much regret any errors or omissions that may nevertheless have occurred.

Dr. Michael I. Solomon
Peter J. Solomon
Dale F. and Dr. Stephen M. Sonnenberg
Sonnensohn, Nath & Rosenthal
Ellen Sonnnow
Karen and Paul Spiegel
Karyn and Dr. Bradley Sporkin
Elyse Staff
Cerie Neger Stahl
Dr. E. Richard Stanley
Elizabeth Steiger
Eileen and Michael R. Stein
Dr. Stephen Stein
Joan and Michael Steinberg
Pamela Stern
Sarah Sternklowr
Taylor Stirling
Ian Stone
Eileen and Dr. Maurice Strahlberg
Elaine Strauss
Marguerite Strauss
Lynn Surry
Dr. Robert Sussman
Dr. Yu D. Ta
Drs. David Tange and Mary Jo Freeman
Drs. Penina Tarshish and Jerome H. Koss
Dr. Naomi P. and Andrew Taylor
Bruce Teitelbaum
Ann B. Terry and Dr. Michael Reich
Kevin Terry
Frances Fish Tompkins
Dr. Christopher M. Tortora
Towne House Restorations, Inc.
Elizabeth Tozzi-Fensterstock
Dr. Bertrand Yu-Hao Tuan
Melanie Tucker
Dr. William W. Tung
Commy and Dr. Okoro C. Ukpabi
Lucia Ullmann
Benita K. and Ronald L. Unger
Dr. Phyllis Ann Vallee
Venus Construction, Ltd.
Meredith Verona
Eugene and Dr. Sara Vogel
Laurie Vogel
Susan Wagner
Lana and Justin P. Walder
Linda S. and David M. Walke
Gerald G. Walker
Hillary Wallace
Dr. Sylvia Wassertheil-Smoller
James Wawrzewski
Jacqueline Weidman
Lorne Weil
Maurice M. Weill
Sara Weiner
Shirley Weinger
Drs. Andrea Weiss and Bruce Schwartz
Arnold Weiss
Carol and Herman H. Weiss
Jody Weisman
Tanya Weitz
Wellington Regional Medical Center
Ilene Wetanson
Dr. Amy R. Wexler
Anita Volz Wien
Sally A. Wilkinson
S. Tamara Winn
Susan Winter
Dr. Harley M. Wishner
Dr. George Witting
Larry Wohl
Carol Wolfe
Myrna R. and Dr. Stuart B. Wollman
Dr. Pauline Woo
David Wood
John W. Wright
Janice G. and Dr. David M. Yamins
Suzanne Yearley
Karen Gantz Zahler
Hope Lisa Ziff
Renate Zimet
Sandra Zimmerman
Marsha Z. Zipser
Lynn Zises
Barbara Zuckerman
Deborah Ann Zuckerman

Estate of Melissa H. Smith
Alexandra and Gurbachan Singh
Saul Simon
Henry A. Singer
Alexandra and Gurbachan Singh
Melissa H. Smith
Judy Snyder
Molly G. Snyder
Barbara L. and Dr. Sidney H. Sobel
Melvin Sobel
Dr. Jonathan G. Solomon

Dr. Joseph A. Salerno
Ellen L. Salsburg
Bette Saltzman
Deborah Sams and Dr. Marc S. Ushat
Lynn and Meyer Sapoff
Dr. Joan Savitsky
Dr. and Mrs. David I. Schachne
Michelle Schechter
Dr. Ronald Schechter
Curtis J. Schenker
Dr. Irwin Scher
Linda R. and Dr. Allan J. Scher
Anita L. and Dr. David Schick
Sherri Schnall
Dr. Abraham T. Schneider
Lauren Schneider
Randi Schor
Dr. Zalman R. Schrader
Judith Schuldernfrei
Harvey Schuelweis
Jules and Dr. Evelyne Schwaber
Dr. Arthur L. Schwartz
Catherine Sosnick Schwartz
Iris Schwartz
Dr. Susan Schwartz
Jill Selring
Jane Shalam
Jane A. and Barton A. Shallat
Dr. Ellyn P. Shander
Leonard Shaykin
Paula and Louis Sheinbaum
Drs. Hanna B. Sherman and Daniel Mark Sheff
Dr. Howard I. Sherman
Dr. Ian M. Shivack
Dr. Sandra E. and Mr. Jed M. Shivers
Jana Shopkorn-Siegel
Sylvia Shulman
Michael Sider
Silk & Halpern Realty Associates
Natasha Silver
Jeffrey Silverman
Dr. Joel W. Silverstein
Lynn Simon and Marc Konigsberg
Saul Simon
Henry A. Singer
Alexandra and Gurbachan Singh
Melissa H. Smith
Judy Snyder
Molly G. Snyder
Barbara L. and Dr. Sidney H. Sobel
Melvin Sobel
Dr. Jonathan G. Solomon

Maurice M. Weill
Sara Weiner
Shirley Weinger
Drs. Andrea Weiss and Bruce Schwartz
Arnold Weiss
Carol and Herman H. Weiss
Jody Weisman
Tanya Weitz
Wellington Regional Medical Center
Ilene Wetanson
Dr. Amy R. Wexler
Anita Volz Wien
Sally A. Wilkinson
S. Tamara Winn
Susan Winter
Dr. Harley M. Wishner
Dr. George Witting
Larry Wohl
Carol Wolfe
Myrna R. and Dr. Stuart B. Wollman
Dr. Pauline Woo
David Wood
John W. Wright
Janice G. and Dr. David M. Yamins
Suzanne Yearley
Karen Gantz Zahler
Hope Lisa Ziff
Renate Zimet
Sandra Zimmerman
Marsha Z. Zipser
Lynn Zises
Barbara Zuckerman
Deborah Ann Zuckerman

Estate of Jeanette Friedman
Estate of Mildred Golombek
Goodstein Memorial Trust
Estate of Manny Hilman
Irma T. Hirschel Trust
Estate of Herbert J. Kanasy
Estate of Estelle Knapp
Estate of Elizabeth Kronovet
Estate of Bertram Leslie
Estate of Dorothy Levine
Estate of Marie Markus
Margaret Sherlin Meltzer Trust
Estate of Joan Miller
Dr. Mildred Morehead
The Estate of Alexander Nadel
Estate of Saul Ritter
Estate of Lila Rudin
Estate of Eve Scheinberg
Estate of Fannie Sender
Estate of Larry Stock

PLEASE NOTE:

Every effort has been made to ensure the accuracy of the information provided. We very much regret any errors or omissions that may nevertheless have occurred.
Healthy Finances Amid Trying Times

Despite the difficult economic climate in fiscal year 2008 (July 2007–June 2008), Einstein did well financially. In fact, this year ranks as the most successful for fund-raising in our history: $62.1 million received from our generous donors. In spite of the adverse economy, we also increased our revenue from grants and contracts, which in FY2008 reached $252 million, an increase of 4% over FY 2007. The accompanying pie charts illustrate our FY2008 financial performance in more detail.

FISCAL YEAR 2008 FINANCIAL RESULTS

**OPERATING REVENUES**

$416,316,431

**OPERATING EXPENSES**

$389,011,603

EINSTEIN PROFILE

M.D. students: 750  
Students in Class of 2011: 183  
Applicants to Class of 2011: 7,300  
Ph.D. students: 350  
Residency programs offered: 150  
Full-time faculty: 564  
Einstein alumni: more than 7,000  
Major research centers funded by NIH: 5  
Physicians in training at Einstein and affiliated hospitals: 2,500

AFFILIATED HOSPITALS

Montefiore Medical Center  
Beth Israel Medical Center  
North Shore–Long Island Jewish Health System  
Bronx–Lebanon Hospital Center  
Jacobi Medical Center